Molecular radioafterglow probes for cancer radiodynamic theranostics
Molecular radio afterglow probes with activatable mechanisms address the limitations of existing cancer radiodynamic theranostics by enabling precise cancer detection and therapy, offering superior sensitivity and specificity for deep tissue imaging and treatment.
Patent Information
- Application Number
- PCT/SG2024/050333
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-20
- Publication Date
- 2024-11-28
AI Technical Summary
Current cancer radiodynamic theranostics face limitations due to the lack of organic molecular radio afterglow probes, which are essential for deep tissue imaging and therapy, as inorganic nanoparticles are biomarker independent and lack specificity, and organic molecules have poor X-ray absorption and short radio-luminescence lifetimes.
Development of molecular radio afterglow probes (MRAPs) with specific activatable mechanisms that include a tumour-targeting moiety, a radio theranostic moiety, and a cleavable moiety, allowing for precise cancer diagnosis and therapy by emitting radio afterglow upon X-ray irradiation.
The MRAPs enable ultrasensitive and specific detection of tumours and perform radiotherapy with molecular precision, providing superb contrast for diminutive tumours and allowing for image-guided surgery and monitoring of cell therapy.
Smart Images

Figure SG2024050333_28112024_PF_FP_ABST
Abstract
Description
[0001] MOLECULAR RADIOAFTERGLOW PROBES FOR CANCER RADIODYNAMIC THERANOSTICS
[0002] Field of Invention
[0003] The present disclosure generally relates to probes for cancer radiodynamic theranostics, and more particularly relates to molecular radio afterglow probes for cancer radiodynamic theranostics.
[0004] Background
[0005] The listing or discussion of a prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.
[0006] Optical imaging agents have been pervasively applied in biology and medicine, providing molecular specificity for diagnosis and phototherapy. However, light-tissue interactions limit the imaging and therapeutic abilities of optical agents to superficial or endoscopically accessible tissues. Therefore, afterglow agents that can store photoenergy and release photons after the cessation of light irradiation have emerged to mitigate this issue. Due to the elimination of tissue autofluorescence, such photoafterglow agents can detect biomarkers in the deep tissue with high sensitivity. However, the prerequisite of light pre-irradiation causes difficulty in the repetitive induction of signal and phototherapeutic action of photoafterglow agents in deep tissues due to the limited penetration depth of light, constraining their translation potential.
[0007] In contrast to light, X-rays have deep-tissue penetration, permitting the delivery of high-energy photons into the human body for diagnostic imaging and cancer radiotherapy. Inspired by the radio-luminescence mechanism, X-rays have been lately exploited to replace light to induce afterglow imaging. However, such radio afterglow imaging (RAI) agents have been rarely reported and limited to a few rare-earth-doped inorganic nanophosphors. Similarly, X-rays can serve as the energy source to initiate the photodynamic process of optical agents to enable radiodynamic therapy (RDT). Due to the localized production of cytotoxic reactive oxygen species (ROS) from optical agents, RDT can minimize the radiation damage to normal tissues and exert tumour ablation in deep tissues. As most photosensitizers do not directly respond to X-rays, inorganic nanophosphors are often used as transducers to down-convert X-ray photons into light for the in situ excitation of photosensitizers. Despite the translational potential of RAI and RDT in oncology, only inorganic-based nanoparticles are available; additionally, because their radio functions are biomarker independent and always switched on, cancer detection and treatment efficacies heavily rely on the concentration difference between tumour and normal tissues, leading to poor specificity. In contrast to inorganic nanoparticles, organic molecules have well-defined structures that facilitate the precision control of physiological properties. However, organic molecules often contain light atoms (such as hydrogen, carbon and oxygen) and weak spin-orbit coupling; thus, they have weak X-ray absorption, short radio-luminescence lifetime and poor singlet oxygen generation on X-ray irradiation. Consequently, no organic molecules have been reported to emit afterglow after X-ray irradiation.
[0008] Therefore, there exists a need for new molecular radio afterglow probes for cancer radiodynamic theranostics.
[0009] Summary of Invention
[0010] Aspects and embodiments of the invention are provided in the following numbered clauses.
[0011] 1. A compound of formula la or lb: where:
[0012] R represents:
[0013] where the wiggly line represents the point of attachment to the rest of the molecule;
[0014] X represents NMe, NEt, CMe2, SiMe2, O, S or Se; each R4 is independently selected from:
[0015] ; or an aromatic or heteroaromatic group that is unsubstituted or substituted by CO2H or OH, where: the wiggly line represents the point of attachment to the rest of the molecule;
[0016] PEG is PEG1 K, PEG2K, or PEG5K; n is 0 to 11 ;
[0017] LINKER represents: where n is 0 to 11 and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the
[0018] where the wiggly line represents the point of attachment to the rest of the molecule; each Rs independently represents H or halo; each R1 represents H, Br or I; each R2 represents H, Cl, Br, or I;
[0019] Rs either represents:
[0020] or R3represents -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is:
[0021] where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptide is selected from:
[0022] where the wavy line represents the point of attachment to the rest of the molecule, or a pharmaceutically acceptable salt or solvate thereof.
[0023] 2. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Clause 1 , wherein the compound has formula la.
[0024] 3. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Clause 1 or Clause 2, wherein R represents: where the wiggly line represents the point of attachment to the rest of the molecule; and X represents NEt , O, S or Se, such as O, S or Se, such as S. 4. The compound, or pharmaceutically acceptable salt or solvate thereof, according to
[0025] Clause 3, wherein R represents: where the wiggly line represents the point of attachment to the rest of the molecule; and
[0026] X represents O, S or Se, such as S.
[0027] 5. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein 4 is independently selected from: where: the wiggly line represents the point of attachment to the rest of the molecule;
[0028] PEG is PEG1 K, PEG2K, or PEG5K; and n is 0 to 11.
[0029] 6. The compound, or pharmaceutically acceptable salt or solvate thereof, according to
[0030] Clause 5, wherein R4is independently selected from: where: the wiggly line represents the point of attachment to the rest of the molecule;
[0031] PEG is PEG1 K, PEG2K, or PEG5K; and n is 3 to 5, such as 4.
[0032] 7. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein, when present, LINKER represents:
[0033] , where n is 3 to 5, such as 4, and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the TARGET GROUP.
[0034] 8. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein, when present, TARGET GROUP represents: where the wiggly line represents the point of attachment to the rest of the molecule.
[0035] 9. The compound, or pharmaceutically acceptable salt or solvate thereof, according to
[0036] Clause 8, wherein, when present, TARGET GROUP represents: where the wiggly line represents the point of attachment to the rest of the molecule.
[0037] 10. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein Ri represents H or I. 11. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein R2 represents H.
[0038] 12. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein R3 either represents: the wavy line represents the point of attachment to the rest of the molecule; or R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is:
[0039] where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule. 13. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein R3 represents -SELF IMMOLATIVE LINKER- PEPTIDE, where the self immolative linker is: where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule.
[0040] 14. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein when R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, the peptide is selected from:
[0041] where the wavy line represents the point of attachment to the rest of the molecule.
[0042] 15. The compound, or pharmaceutically acceptable salt or solvate thereof, according to
[0043] Clause 14, wherein when Rs represents
[0044] -SELF IMMOLATIVE LINKER-PEPTIDE, the peptide is: where the wavy line represents the point of attachment to the rest of the molecule. 16. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding clauses, wherein:
[0045] Ri is I;
[0046] R2is H;
[0047] R is: the wavy line represents the point of attachment to the rest of the molecule;
[0048] R4 is the wiggly line represents the point of attachment to the rest of the molecule;
[0049] R3is -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptide the wavy line represents the point of attachment to the rest of the molecule.
[0050] 17. A method for detection of cancer in vivo, the method comprising the following steps:
[0051] (ai) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to any one of Clauses 1 to 16 to a subject; and
[0052] (aii) detecting any chemiluminescence, wherein the presence of cancer in vivo is indicated by chemiluminescence.
[0053] 18. A method of treating cancer, the method comprising the following steps:
[0054] (bi) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to any one of Clauses 1 to 16 to a subject; and
[0055] (bii) subjecting the subject to X-ray irradiation.
[0056] 19. The method according to Clause 18, wherein the compound of formula la or formula lb, or salt or solvate thereof, is a compound in which R4 is
[0057] Drawings
[0058] Fig. 1 depicts synthetic routes for radio afterglow candidates, (a) Synthesis of intermediate 4: (i) NaBH4, methanol, r.t., 30 min, 100% yield; (ii) ICI, NaOH, methanol, 0 °C, 1 h, 75%; (iii) pyridinium dichromate, pyridine, dichloromethane, r.t., 3 h, 68% yield, (b) Synthetic route for DPANand IDPAN: (iv) quinoline, iodoethane, acetonitrile (ACN), reflux, overnight, 85% yield; (v) compound 5, Na, ethanol (EtOH), malononitrile, 0 °C, 71% yield; (vi) for DPAN: piperidine, DBQP, compound 1, ACN, reflux, N2, 6 h, 92% yield; for IDPAN: piperidine, DBQP, compound 4, ACN, reflux, N2, 6 h, 87% yield, (c) Synthetic route for DPAOand IDPAO. (vii) 2Z- hydroxyacetophenone, ethyl acetate, NaH, THF, r.t. to reflux, overnight; then HCI, MeOH, r.t., 14 h, 65% yield; (viii) malononitrile, acetic anhydride, reflux, 2 h, 71% yield; (ix) for DPAo: piperidine, DBP, compound 1 , ACN, reflux, N2, 2 h, 81%; for I DPAo: piperidine, DBP, compound 4, ACN, reflux, N2, 6 h, 67% yield, (d) Synthetic route for DPAsu and IDPAsu: (x) thiophenol, polyphosphoric acid, 90 °C, 1 h, 68% yield; (xi) compound 6, malononitrile, acetic anhydride, reflux, 2 h, 53% yield; (xii) for DPAsu: piperidine, DBTP, compound 1 , ACN, reflux, N2, 2 h, 76% yield; for IDPAsu: piperidine, DBTP, compound 4, ACN, reflux, N2, 2 h, 63% yield, (e) Synthetic route for DPAse and IDPAse: (xiii) 2-bromobenzaldehyde, propynylmagnesium bromide, THF, r.t., 1 h, 100% yield; (xiv) o-iodoxybenzoic acid, dimethylsulfoxide (DMSO), r.t., 96% yield; (xv) Se, NaBH4, DMF, 105 °C, 85% yield; (xvi) compound 10, Malononitrile, acetic anhydride, reflux, 2 h, 31 % yield; (xvii) for DPAse: piperidine, DBSeP, compound 1 , ACN, reflux, N2, 2 h, 52%; for IDPAse: piperidine, DBSeP, compound 4, ACN, reflux, N2, 2 h, 38% yield.
[0059] Fig. 2 depicts the normalized ultraviolet (UV) spectra of radio afterglow candidates (a,b) before and (c,d) after Xray irradiation at 250 pGys1for 20 s in phosphate buffered saline (PBS, 0.01 M, pH 7.4, 50% DMSO, V / V) solution.
[0060] Fig. 3 depicts the normalized fluorescence spectra of radio afterglow candidates (a,b) before and (c,d) after X-ray irradiation at 250 pGy- S'1for 20 s in PBS (0.01 M, pH 7.4, 50% DMSO, V / ) solution at 450 nm excitation.
[0061] Fig. 4 depicts synthesis and characterization of radio afterglow dynamic luminophores. (a) Chemical structures of DPAs and IDPAs. (b) Schematic of the proposed radio afterglow mechanism. X-ray photons first interact with atoms in IDPAx through the photoelectric effect and Compton scattering, ejecting high-energy electrons (ionization). These hot electrons further interact with the surrounding atoms, eliciting a cascade of secondary electrons with decreased energy and formation of electron-hole pairs (thermalization). Owing to the presence of iodine and sulfur, a large number of electrons are populated as triplet excitons. These excitons jump back to the ground state, transferring energy to the surrounding oxygen molecules and generating1O2 (sensitization). The in situ-generated1O2 reacts with IDPAx via a cycloaddition reaction and converts it into a dioxetane intermediate. At last, this intermediate gradually decomposes into the corresponding activated products (activated IDPAx) and releases photons (afterglow), (c-e) Radio afterglow spectra (c), intensities (d) and half-lives (e) of DPAs and IDPAs (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) after X-ray irradiation (5 mGy, 250 pGy s-1for 20 s) (n = 3 independent experiments), (f) Radio afterglow intensities of IDPAsu after ten cycles of X-ray irradiation. X-ray was ‘on’ at 250 pGy s-1for 20 s and ‘off for 12 h in each cycle (n = 3 independent experiments), (g) High-performance liquid chromatography (HPLC) analysis of IDPAsu before and after X-ray irradiation (2 Gy, 100 mGy s’1for 20 s). (h) Electron spin resonance (ESR) spectra showing1C>2 generation from IDPAsu (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) before and after X-ray irradiation (5 mGy, 250 pGy s-1for 20 s) by 2,2,6,6-tetramethylpiperidine (TEMP) as the trapping agent and NaNs (1 mM) as the1C>2 quencher, (i)1C>2 generation from DPAs, IDPAs (100 pM) and commercial radio sensitizers (acridine orange (AO), hematoporphyrin (HP) and verteporfin (VP)) in PBS (0.01 M, pH 7.4, 50% DMSO) after X-ray irradiation at 250 pGy s-1for 20 s (n = 3 independent experiments). Data were presented as mean ± s.d.
[0062] Fig. 5 depicts (a) decay of radio afterglow from candidates (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) solution after X-ray irradiation at 250 pGy- s_1for 20s. (b) Representative images of radio afterglow from IDPASu solution at different timepoints (10, 120, 360, 720, 1200 and 1500 min) after X-ray irradiation at 250 pGy s-1for 20 s.
[0063] Fig. 6 depicts HPLC analysis of IDPAsu after one and 10 on-off cycles of radio afterglow (each cycle at 250 pGys1for 20 s).
[0064] Fig. 7 depicts radio afterglow mechanism and photophysical property study, (a) Proposed radio afterglow mechanism of IDPASu and HRMS analysis of the new peaks at 6.0 (b) and 14.8 min (c) in Fig. 4g, confirming the generation of dioxetane intermediate and activated IDPAsu. (d) Radio afterglow intensity of IDPAsu as a function of its concentration in PBS (0.01 M, pH 7.4, 50% DMSO) after X-ray irradiation at 250 pGys-1for 20 s. Data were presented as mean ± s.d (n = 3 independent experiments), (e) Temperature of PBS and IDPAsu (100 mM) in PBS (0.01 M, pH 7.4, 50% DMSO) before and after X-ray irradiation at 250 pGys-1for 20 s at room temperature. Data were presented as mean ± s.d (n = 3 independent experiments).
[0065] Fig. 8 depicts (a) chemical structure of DIDPAo and DIDPAs. Radio afterglow intensity of DIDPAo (b) and DIDPAs (c) (100 mM) after X-ray irradiation at different dosages (0, 5, 50 and 500 mGy) in PBS (0.01 M, pH 7.4, 50% DMSO, VA / ) solution. ESR spectra for1O2 generation from DIDPAo (d) and DIDPAs (e) with and without X-ray irradiation (5 mGy). (f) Quantification of ESR signal from (d) and (e).
[0066] Fig. 9 depicts standard curve relationship between the ESR signal and different concentrations of1O2 when incubated with TEMP (10 mM). Data were presented as mean ± s.d., n = 3 independent experiments.1C>2 was quantitatively generated by addition of NaOCI to H2O2.
[0067] Fig. 10 depicts detection of O2 and - OH generated from IDPAsu solution upon X-ray irradiation, (a) Mechanism of DHR123 probe for Oz" detection, (b) Fluorescence signals of DHR123 as a function of concentrations of O2 " at Aex505 nm and Aem534 nm. Data were presented as mean ± s.d., n = 3 independent experiments, (c) Fluorescence signals of DHR123 in the presence of IDPAsu (10 pM) upon X-ray irradiation of 0, 5 mGy (250 pGy- s'1for 20 s), and 2 Gy (100 mGy- S'1for 20 s) in PBS (0.01 M, pH 7.4, containing 50% DMSO) solution. Statistical significance was calculated via one-way ANOVA with a Tukey post-hoc test, DHR123 (+ X-ray, 250 pGy-S’1for 20 s or 100 mGy-S’1for 20 s) versus DHR123 (- X- ray), ns: not significant while DHR123 + IDPASu(+ X-ray, 100 mGy- S’1) versus DHR123 + IDPAsu (- X-ray), ****p = 2x106. Data were presented as mean ± s.d., n = 3 independent experiments, (d) Mechanism of HPF probe for ■ OH detection, (e) Fluorescence signals of HPF as a function of the concentrations of - OH at Aex450 nm and Aem515 nm. Data ware presented as mean ± s.d., n = 3 independent experiments, (f) Fluorescence signals of DHR123 in the presence of IDPAsu upon different dosages of X-ray irradiation in PBS (0.01 M, pH 7.4, containing 50% DMF) solution. Data were presented as mean ± s.d (n = 3 independent experiments). Statistical significance was calculated via one-way ANOVA with a Tukey post- hoc test; HPF (+ X-ray, 250 pGy s-1for 20 s or 100 mGys'1for 20 s) versus HPF (- X-ray): ns: not significant; HPF + IDPAsu (+ X-ray, 250 pGy- S’1for 20 s or 100 mGy- S’1for 20 s) versus HPF + IDPAsu (- X-ray): ns: not significant.
[0068] Fig. 11 depicts deep-tissue radio afterglow dynamic process, (a) Schematic of afterglow induction through chicken breast tissue by X-ray or light irradiation and detection without chicken breast tissue. The X-ray source and xenon lamp were optimized to ensure that all the samples at 0 cm (without coverage) received the same dose of X-rays (5 mGy, 250 pGy s~1for 20 s) or light (180 mW cm-2for 20 s) and then the afterglow signal was recorded without chicken breast tissues, (b) Schematic of the advantages of radio afterglow over photoafterglow, (c)1C>2 generation from IDPAsu (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) after X-ray or light irradiation through chicken breast tissues (n = 3 independent experiments), (d) Afterglow images of IDPAsu (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) after X-ray or light irradiation at different tissue depths, (e) Signals of radio afterglow and photoafterglow at different tissue depths (scale breaks from 0.01 to 0.02) (n = 3 independent experiments). Data are presented as mean ± s.d. Fig. 12 depicts (a,b) cell viabilities of U87 cells incubated with IDPAsu at different concentrations (0, 2.5, 5, 10. 25, 50, and 100 pM) for 24 h without (a) and with X-ray irradiation through chicken breast tissue of different thicknesses (0, 5, 8 and 15 cm) (b). All data were presented as mean ± s.d., n = 5 independent experiments.
[0069] Fig. 13 depicts (a) representative radio afterglow images of tumor-free Balb / c nude mice subcutaneously injected with 20 pl of I DPAsusolution at different concentrations (100, 50, 20, 10, 5, 1, 0.5, 0 pM). (b) Radio afterglow intensities as a function of IDPAsu concentrations in (a). Mice were irradiated with Xray at 5 mGy (250 pGy- s-1for 20 s) prior to signal detection with the acquisition time of 60 s. Data were presented as mean ± s.d (n = 3 independent mice).
[0070] Fig. 14 depicts in vivo radio afterglow imaging and radiodynamic therapy after intratumoral injection of IDPAsu- (a) Schematic illustration of IDPASu-mediated cancer theranostics in subcutaneous U87 tumor-bearing mice, (b) In vivo radio afterglow spectra on U87 tumors of nude mice at 0.5 h post-injection of IDPAsu (0.1 pmol - kg-1) with and without X-ray irradiation at 5 mGy (250 pGy - s-1for 20 s) with each emission with automatic exposure time. (c,d) Representative radio afterglow images (c) and radio afterglow intensities (d) on tumors of living nude mice at 0, 0.5, 1 , 4, 6, 8, 12, 16, or 24 h post-injection of IDPAsu (0.1 pmol - kg-1) in PBS (0.01 M, pH 7.4). IDPAsu was solubilized by (2-carboxyethyl)-p-cyclodextrin sodium salt (p- CD, 0.1 pmol - kg-1). At each timepoint, mice were irradiated with X-ray at 5 mGy (250 pGy- s-1for 20 s) followed by signal detection with the acquisition time of 60 s. Data were presented as mean ± s.d., n = 3 independent mice, (e) Confocal fluorescence images of tumor tissues from PBS and IDPASu-injected (0.1 pmol - kg-1) U87-tumor-bearing mice with or without X-ray irradiation (0.1 Gy, 5 mGy- s-1for 20 s). Blue fluorescence signals from cell nucleus stained with DAPI, and green fluorescence signals from tumor tissues stained with Singlet Oxygen Sensor Green (SOSG). (f) Quantification of SOSG signals in tumor tissues (e) (n = 3 mice). (g,h) Tumor growth (g) and body weight (h) curves of U87 tumor-bearing mice after indicated treatments (n = 5 mice). Statistical significance in (g) was calculated by two-tailed Student’s t- test; PBS+X-ray versus PBS group: ns: not significant while IDPASu+X-ray versus PBS group ****p > 3 7xio-5. (i, j) Confocal fluorescence images of TUNEL-stained tumor tissues after indicated treatments. Nuclei were stained with DAPI (blue), and DNA fragments were stained with TUNEL (green) (n = 3 independent experiments), (j) Representative images of haematoxylin and eosin (H&E)-stained tumor tissues after indicated treatments (n = 3 independent experiments). Fig. 15 depicts in vitro studies for radio afterglow dynamic cancer theranostics. (a) Schematic of the sensing mechanism of MRAP for cathepsin B (CatB). (b) Radio afterglow spectra of molecular radio afterglow dynamic probe (MRAP, 100 pM) in the presence and absence of CatB (5 pg mh1) in PBS (0.01 M, pH 7.4), EDTA (1 mM) and glutathione (5 mM) for 6 h incubation. X-ray irradiation: 5 mGy, 250 pGy s"1for 20 s. (c) Radio afterglow signals of MRAP (100 pM) after 6 h incubation with different enzymes (ALP, APN, furin, GGT, NTR, (3-gal, uPA and CatB). X-ray irradiation: 5 mGy, 250 pGy s"1for 20 s (n = 3 independent experiments), (d) ESR spectra for1C>2 generation from MRAP before and after the cleavage of CatB with and without X-ray irradiation (2 Gy, 100 mGy s"1for 20 s). (e) Schematic of activatable RAI and RDT of MRAP for CatB-overexpressed U87 cells, (f) Radio afterglow intensities of U87 and 3T3 cells at different numbers (1 , 2 and 4 x 104per well) after incubation with MRAP (100 pM) for 10 h. X-ray irradiation: 5 mGy, 250 pGy s"1for 20 s. The control group (U87 + CA-074): U87 cells were preincubated with CA-074 (1 mM) for 10 h (n = 4 independent experiments). The inset shows the representative radio afterglow images of U87 and 3T3 cells after the indicated treatments, (g) Viabilities of CatBnegative cells (3T3, RAW 264.7, THP-1 and 293- T) and CatB-positive cells (U87, 4T1 , B16-F10 and A549) after incubation with MRAP at different concentrations for 24 h. X-ray irradiation: 2 Gy, 100 mGy s"1for 20 s (n = 5 independent experiments). Data are presented as mean ± s.d.
[0071] Fig. 16 depicts (a) synthesis of uncaged MRAP: (i) ethyl acetoacetate, 4-methoxybenzenethiol, polyphosphate, 90 °C, 30 min, 68% yield; (ii) compound 11 , BBr3, dichloromethane (DCM), 0 °C, 6 h, 95% yield; (iii) compound 12, K2CO3, 1-azido-4-iodobutane, DMF, 80 °C, overnight, 87% yield; (iv) compound 13, malononitrile, AcOAc, 140 °C, 60 min, 45% yield; (v) compound 14, piperidine, compound 4, ACN, reflux, N2, 2 h, 92% yield; (vi) compound 15, CuSO4' 5H2O, ascorbic acid sodium, DMSO / H2O (V / V, 9 / 1), alkyne-PEG2000-cRGD, 95% yield, (b) Synthetic route for activatable MRAP and cRGD-free MRAP: (vii) NaHCO3, dimethoxyethane, 16 h, from 0 °C to r.t., 96% yield, (viii) N-ethoxycarbonyl-2-ethoxy-1 ,2-dihydroquinoline, THF, 8 h, r.t., 90% yield; (ix) PBr3, THF, 0 °C, without purification; (x) Cs2CO3, GCOs, ACN, overnight, r.t., 67% yield; (xi) water-soluble moiety (alkyne-PEG2000-cRGD or alkyne- PEG20000Me), CuSC>4 ■ 5H2O, ascorbic acid sodium, DMSO / H2O (V / V, 9 / 1), equivalent production (MRAP and cRGD-free MRAP).
[0072] Fig. 17 depicts (a,b) absorbance (a), fluorescence (b) spectra of MRAP (100 pM) in absence and presence of cathepsin B (CatB, 5 pg / mL) in PBS (0.01 M, pH 7.4, 1 mM EDTA, 5 mM glutathione) for 6 h incubation at X-ray irradiation (5 mGy: 250 pGy- S"1for 20 s). (c) HPLC analysis of MRAP precursor compound 18 before and after cleavage by CatB. (d) Radio afterglow intensities of MRAP (100 pM) after incubation with CatB activation, followed by X- ray irradiation (n = 3 independent experiments, mean ± s.d.). (e) Radio afterglow intensities of MRAP as a function of CatB concentrations after X-ray irradiation (n = 3 independent experiments, mean ± s.d.). (f)1O2 generation of MRAP (100 pM) in the presence of CatB (5 pg / mL) upon X-ray irradiation through different chicken breast tissue depths (n = 3 independent experiments, mean ± s.d ). Two-tailed Student’s t-test; thickness at 15 cm group versus -CatB group, *p = 0.023.
[0073] Fig. 18 depicts (a) viabilities of U87 cells incubated with MRAP at different concentrations for 24 h (n = 5 independent experiments, mean ± s.d ). (b,c) Viabilities of U87 (b) and 3T3 cells
[0074] (c) incubated with MRAP at different concentrations for 24 h and irradiated with X-ray through chicken breast tissues of different thicknesses (n = 5 independent experiments, mean ± s.d ).
[0075] (d) Viability of U87 cells pre-treated with CA-074 (1 mM, CatB inhibitor) for 10 h and incubated with MRAP without covered tissue, followed by X-ray irradiation at 0 and 2 Gy (100 mGy- s-1for 20 s) (n = 5 independent experiments). Data were shown as mean ± s.d.
[0076] Fig. 19 depicts MRAP-mediated RAI and RDT. (a) Schematic of MRAP for RAI and RDT of orthotopic glioblastoma, (b) Representative radio afterglow images of mice at different timepoints (0, 2, 6, 12, 24, 36 and 72 h) after an intravenous injection of MRAP and cRGD- free MRAP (10 pmol kg-1) with X-ray irradiation (5 mGy, 250 pGy s-1for 20 s). (c) Radio afterglow intensities of brain areas of mice in b as a function of post-injection time (n = 3 independent mice). Two-tailed Student’s f-test; MRAP versus MRAP (no tumour), ***p = 8 x 10~4. (d,e) Tumour growth (d) and survival rate (e) curves of U87-tumour-bearing mice after the indicated treatments (n = 5 independent mice). The irradiation groups under X-ray irradiation at 0.8 Gy (40 mGy S“1for 20 s) for four fractions. Two-tailed Student’s t-test; MRAP + X-ray versus PBS, ****p = 6 x 10"6. (f) Representative images and tumour areas of H&E- stained brain sections of mice treated with PBS + X-ray and MRAP + X-ray on day 21. Tumour areas: PBS + X-ray (average, -9.24 mm2), MRAP + X-ray (average, -1.61 mm2). Data are presented as mean ± s.d., n = 3 independent mice, (g) Histological analysis of H&E- and immunofluorescence-stained sections of the orthotopic glioblastoma of mice treated with PBS and MRAP with or without X-ray irradiation. Nuclei stained with DAPI (blue), tissue1O2 shown by SOSG (green), caspase-1 stained with anti-caspase- 1 antibody (red) and DNA fragments stained with TUNEL (green) (n = 3 independent experiments).
[0077] Fig. 20 depicts biodistribution and pharmacokinetics studies, (a) Quantification of cRGD-free MRAP and MRAP in main organs from orthotopic U87 tumor-bearing nude mice at 24 h after intravenous injection of the corresponding probe (10 pmohkg-1) (n = 3 independent mice). (b,c) The percent injected dose (ID%) of MRAP (b) and cRGD-free MRAP (c) in blood circulation after intravenous injection (10 pmol - kg-1) into healthy nude mice (n = 3 independent mice). Data were shown as mean ± s.d.
[0078] Fig. 21 depicts bioluminescence imaging of orthotopic U87-Luc tumor-bearing mice at day 0, 3, 6, 9, 12, 15, 18, and 21 during indicated treatments (n = 5 mice).
[0079] Fig. 22 depicts (a) representative images of H&E staining of whole brain sections from PBS and MRAP groups at day 21 and an enlarged view of tumor area from MRAP+X-ray and PBS+X-ray groups (Fig. 19f). (b) Body weight of U87 tumor-bearing mice after indicated treatments (n = 5 mice, mean ± s.d.). (c) Histological analysis of the major organs. Histological H&E-stained main organs of mice collected staining of heart, liver, lung and kidney from intracranial U87 tumor-bearing nude mice sacrificed after 21 days of evaluation. Images are representative of three biologically independent mice.
[0080] Fig. 23 depicts MRAP-mediated ultrasmall-tumour detection and precision tumour ablation, (a) Schematic of radio afterglow and bioluminescence for ultrasmall-tumour detection, (b) Representative bioluminescence and radio afterglow images of U87-Luc-tumour-bearing mice with different tumour sizes. The mice were intraperitoneally injected with d-luciferin, sodium salt (500 pmol kg-1) or intravenously injected with MRAP (10 pmol kg-1) with X-ray irradiation (5 mGy, 250 pGy S"1for 20 s) before imaging, (c) Radio afterglow and bioluminescence intensities as a function of tumour sizes (n = 3 independent mice), (d) Schematic, in vivo and ex vivo RAI of brain areas for biocompatibility and precise therapy studies. U87-Luc-tumour- bearing mice were locally injected with MRAP or uncaged MRAP (0.5 pmol kg-1) at 30 min before X-ray irradiation (2 Gy, 100 mGy S“1for 20 s) and RAI (120 s acquisition time), (e) Chemical structure of always-on uncaged MRAP. (f) Radio afterglow intensities of in vivo and ex vivo images of the brain areas in d (n = 3 independent mice), (g) H&E and immunofluorescent section staining studies of the brain sections from d. Nuclei were stained with DAPI (blue) and caspase-3 was stained by anti-caspase-3 antibody (red).
[0081] Fig. 24 depicts routine blood analysis of normal Kunming mice after intravenous injections with PBS, cRGD-free MRAP (20 pmol - kg-1) and MRAP (20 pmol- kg-1) with a dose interval of 24 h for once and five times, respectively (n = 3 independent mice). Data were shown as mean ± s.d.. WBC: white blood cells (normal range: 0.8-6.8); Lymph#: lymphocyte number (normal range: 0.7-5.7); Mon#: monocyte number (normal range: 0.0-0.3); Gran#: granulocyte number (normal range: 0.1-1.8); Lymph%: lymphocyte (%) (normal range: 55.8-90.6); Mon%: monocyte (%) (normal range: 1.8-6.0); Gran%: granulocyte (%) (normal range: 8.6-38.9); RBC: red blood cells (normal range: 6.36-9.42); HGB: hemoglobin (normal range: 110-143); HCT: hematocrit (normal range: 34.6-44.6); MCV: Mean Corpuscular Volume (normal range: 48.2-58.3); MCH: Mean Corpuscular Hemoglobin (normal range: 15.8-19); MCHC: Mean Corpuscular Hemoglobin Concentration (normal range: 302-353); RDW: Red Cell Distribution Width (normal range: 13-17); PLT: Platelets (normal range: 450-1590); MPV: Mean Platelet Volume (normal range: 3.8-6.0).
[0082] Fig. 25 depicts (a) schematic illustration of radio afterglow and photoafterglow induction and detection through chicken breast tissue, (b) Signal-to-background ratio (SBR) of radio afterglow and photoafterglow of IDPAsu (100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) placed under chicken breast tissue with different thickness (0, 1 , 2, 4, 4.5 and 5 cm) after X-ray irradiation or white light irradiation. Data were presented as mean ± s.d. (n = 3 independent experiments). X-ray source and Xenon lamp were optimized to ensure that all samples at 0 cm (without coverage) received same dose of X-ray (5 mGy, 250 pGys-1for 20 s) or light (180 mW’cnr2for 20 s) and then afterglow signal was recorded with chicken breast tissues, (c) Representative images of radio afterglow and photoafterglow of IDPASu(100 pM) in PBS (0.01 M, pH 7.4, 50% DMSO) placed under chicken breast tissue with different thickness (0, 1 , 2, 4, 4.5 and 5 cm) after X-ray irradiation or white light irradiation.
[0083] Description
[0084] It has been surprisingly found that the compounds disclosed herein are activatable nearinfrared radio afterglow probes for cancer radiodynamic theranostics. These compounds allow the detection of a diminutive tumour with superb contrast and perform radiotherapy for deep- seated tumour with molecular precision at a low dosage. Further, modification of these compounds can potentially allow for image-guided surgery and for monitoring cell therapy.
[0085] Thus, in a first aspect of the invention, there is provided a compound of formula la or lb: where the wiggly line represents the point of attachment to the rest of the molecule;
[0086] X represents NMe, NEt, CMe2, SIMe2, O, S or Se; each R4 is independently selected from:
[0087] ; or an aromatic or heteroaromatic group that is unsubstituted or substituted by CO2H or OH, where: the wiggly line represents the point of attachment to the rest of the molecule;
[0088] PEG is PEG1 K, PEG2K, or PEG5K; n is O to 11 ;
[0089] LINKER represents: where n is 0 to 11 and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the TARGET GROUP;
[0090] TARGET GROUP represents: where the wiggly line represents the point of attachment to the rest of the molecule; each Rs independently represents H or halo; each R1 represents H, Br or I; each R2 represents H, Cl, Br, or I;
[0091] Rs either represents: the wavy line represents the point of attachment to the rest of the molecule; or R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is: where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptide is selected from: where the wavy line represents the point of attachment to the rest of the molecule, or a pharmaceutically acceptable salt or solvate thereof.
[0092] In embodiments herein, the word “comprising” may be interpreted as requiring the features mentioned, but not limiting the presence of other features. Alternatively, the word “comprising” may also relate to the situation where only the components / features listed are intended to be present (e.g. the word “comprising” may be replaced by the phrases “consists of” or “consists essentially of”). It is explicitly contemplated that both the broader and narrower interpretations can be applied to all aspects and embodiments of the present invention. In other words, the word “comprising” and synonyms thereof may be replaced by the phrase “consisting of’ or the phrase “consists essentially of’ or synonyms thereof and vice versa.
[0093] The phrase, “consists essentially of’ and its pseudonyms may be interpreted herein to refer to a material where minor impurities may be present. For example, the material may be greater than or equal to 90% pure, such as greater than 95% pure, such as greater than 97% pure, such as greater than 99% pure, such as greater than 99.9% pure, such as greater than 99.99% pure, such as greater than 99.999% pure, such as 100% pure.
[0094] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes mixtures of two or more such compounds, reference to “a composition” includes mixtures of two or more such compositions, and the like.
[0095] A series of molecular radio afterglow probes (MRAPs) for cancer radiodynamic theranostics have been developed. Due to their unique activatable mechanisms, MRAPs can be used for ultrasensitive and specific detection of tumours.
[0096] The compounds of formula la and formula lb (and salts and / or solvates thereof) may be particularly suited to use in in vivo cancer radio afterglowdynamic theranostics. In part, this is because the compounds of formula la and formula lb contain at least one moiety that can be activated to provide radio afterglow, as described in more detail below. Further, the compounds of formula la and formula lb may be particularly suited to the above application because of the presence of a cleavable moiety, as described in more detail below. Without wishing to be bound by theory, the addition of a cleavable moiety allows activation of the radio afterglow and radiodynamic functions of the compounds of formula la and formula lb in the presence of a tumour biomarker, thus enabling precision cancer diagnosis and therapy (see Example 5). In addition, the compounds of formula la and formula lb are particularly suited to the above application because of the presence of a tumour-targeting moiety, as described in more detail below. Without wishing to be bound by theory, the addition of a target group allows targeting towards avp3 integrin overexpressed in tumours (see Example 6). This thereby improves the specificity of the compounds in detecting cancers.
[0097] Thus, in certain embodiments disclosed herein, compounds of formula la and formula lb may be designed to contain a tumour-targeting moiety, a radio theranostic moiety, and a cleavable moiety conjugated to a self-immolative linker (see Fig. 15a). As mentioned above, the compounds of formula la and formula lb contain at least one moiety that can be activated to provide radio afterglow. For example, the moiety may be an organic luminophore (IDPA).
[0098] When used herein, the term “PEG” is intended to refer to “polyethylene glycol”.
[0099] References herein (in any aspect or embodiment of the invention) to compounds of formulae la and lb includes references to such compounds per se, to tautomers of such compounds, as well as to pharmaceutically acceptable salts and / or solvates of such compounds. References to compounds of formulae la and lb may also include reference to pharmaceutically functional derivatives of such compounds.
[0100] Pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula la or lb with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of formula la or lb in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
[0101] Examples of acid addition salts include acid addition salts formed with acetic, 2,2- dichloroacetic, adipic, alginic, aryl sulphonic acids (e.g. benzenesulphonic, naphthalene-2- sulphonic, naphthalene-1 ,5-disulphonic and p-toluenesulphonic), ascorbic (e.g. L-ascorbic), L-aspartic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulphonic, (+)- (1 S)-camphor-10-sulphonic, capric, caproic, caprylic, cinnamic, citric, cyclamic, dodecylsulphuric, ethane-1,2-disulphonic, ethanesulphonic, 2-hydroxyethanesulphonic, formic, fumaric, galactaric, gentisic, glucoheptonic, gluconic (e.g. D-gluconic), glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), a-oxoglutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isethionic, lactic (e.g. (+)-L-lactic and (±)-DL-lactic), lactobionic, maleic, malic (e.g. (-)-L-malic), malonic, (±)-DL-mandelic, metaphosphoric, methanesulphonic, 1- hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulphuric, tannic, tartaric (e.g.(+)-L-tartaric), thiocyanic, undecylenic and valeric acids.
[0102] Particular examples of salts are salts derived from mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids; from organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, arylsulphonic acids; and from metals such as sodium, magnesium, or preferably, potassium and calcium.
[0103] As mentioned above, also encompassed by formula la and lb are any solvates of the compounds and their salts. Preferred solvates are solvates formed by the incorporation into the solid state structure (e.g. crystal structure) of the compounds of the invention of molecules of a non-toxic pharmaceutically acceptable solvent (referred to below as the solvating solvent). Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulphoxide. Solvates can be prepared by recrystallising the compounds of the invention with a solvent or mixture of solvents containing the solvating solvent. Whether or not a solvate has been formed in any given instance can be determined by subjecting crystals of the compound to analysis using well known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography.
[0104] The solvates can be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, and examples of hydrates include hemihydrates, monohydrates and di hydrates.
[0105] For a more detailed discussion of solvates and the methods used to make and characterise them, see Bryn et al., Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
[0106] “Pharmaceutically functional derivatives” of compounds of formula la or formula lb as defined herein includes ester derivatives and / or derivatives that have, or provide for, the same biological function and / or activity as any relevant compound of the invention. Thus, for the purposes of this invention, the term also includes prodrugs of compounds of formula la or formula lb.
[0107] The term “prodrug” of a relevant compound of formula la or formula lb includes any compound that, following oral or parenteral administration, is metabolised in vivo to form that compound in an experimentally-detectable amount, and within a predetermined time (e g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)).
[0108] Prodrugs of compounds of formula la or formula lb may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesizing the parent compound with a prodrug substituent. Prodrugs include compounds of formula la or formula lb wherein a hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group in a compound of formula la or formula lb is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group, respectively.
[0109] Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxyl functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N- Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. “Design of Prodrugs” p. 1-92, Elsevier, New York-Oxford (1985).
[0110] Compounds of formula la, as well as pharmaceutically acceptable salts, solvates and pharmaceutically functional derivatives of such compounds are, for the sake of brevity, hereinafter referred to together as the “compounds of formula la”. Compounds of formula lb, as well as pharmaceutically acceptable salts and / or solvates of such compounds are, for the sake of brevity, hereinafter referred to together as the “compounds of formula lb”.
[0111] Compounds of formula la or lb may contain double bonds and may thus exist as E (entgegen) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.
[0112] Compounds of formula la or lb may exist as regioisomers and may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.
[0113] Compounds of formula la or lb may contain one or more asymmetric carbon atoms and may therefore exhibit optical and / or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a ‘chiral pool’ method), by reaction of the appropriate starting material with a ‘chiral auxiliary’ which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person. All stereoisomers and mixtures thereof are included within the scope of the invention.
[0114] Unless otherwise stated, the term “aryl” when used herein includes CB- (such as Ce-w) aryl groups. Such groups may be monocyclic, bicyclic or tricyclic and have between 6 and 14 ring carbon atoms, in which at least one ring is aromatic. The point of attachment of aryl groups may be via any atom of the ring system. However, when aryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring. Ce-14 aryl groups include phenyl, naphthyl and the like, such as 1 ,2,3,4-tetrahydronaphthyl, indanyl, indenyl and fluorenyl. Embodiments of the invention that may be mentioned include those in which aryl is phenyl.
[0115] Unless otherwise stated, the term “alkyl” refers to an unbranched or branched, cyclic, saturated or unsaturated (so forming, for example, an alkenyl or alkynyl) hydrocarbyl radical, which may be substituted or unsubstituted (with, for example, one or more halo atoms). Where the term “alkyl” refers to an acyclic group, it is preferably CMO alkyl and, more preferably, Ci-e alkyl (such as ethyl, propyl, (e.g. n-propyl or isopropyl), butyl (e.g. branched or unbranched butyl), pentyl or, more preferably, methyl). Where the term “alkyl” is a cyclic group (which may be where the group “cycloalkyl” is specified), it is preferably C3-12 cycloalkyl and, more preferably, C5.10 (e.g. C5.7) cycloalkyl.
[0116] Further embodiments of the invention that may be mentioned include those in which the compound of formula la or formula lb is isotopically labelled. However, other, particular embodiments of the invention that may be mentioned include those in which the compound of formula la or formula lb is not isotopically labelled.
[0117] The term "isotopically labelled", when used herein includes references to compounds of formula I in which there is a non-natural isotope (or a non-natural distribution of isotopes) at one or more positions in the compound. References herein to "one or more positions in the compound" will be understood by those skilled in the art to refer to one or more of the atoms of the compound of formula la or formula lb. Thus, the term "isotopically labelled" includes references to compounds of formula la or formula lb that are isotopically enriched at one or more positions in the compound.
[0118] The isotopic labelling or enrichment of the compound of formula la or formula lb may be with a radioactive or non-radioactive isotope of any of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, bromine and / or iodine. Particular isotopes that may be mentioned in this respect include2H,3H,11C,13C,14C,13N,15N,15O,17O,180,35S,18F,37CI,77Br,82Br and125l). When the compound of formula la or formula lb is labelled or enriched with a radioactive or nonradioactive isotope, compounds of formula la or formula lb that may be mentioned include those in which at least one atom in the compound displays an isotopic distribution in which a radioactive or non-radioactive isotope of the atom in question is present in levels at least 10% (e.g. from 10% to 5000%, particularly from 50% to 1000% and more particularly from 100% to 500%) above the natural level of that radioactive or non-radioactive isotope.
[0119] In order to ensure that the compounds of formula la and formula lb are delivered to cancer cells, R4 may represent
[0120] When used herein, the term “ ” is intended to refer to a target group conjugated to PEG by way of a covalent bond, and the PEG conjugated to bywayOfacovalent bond. Examples of target groups have been provided above. Any suitable linker may be used in the current invention.
[0121] When used herein, the term “self-immolative linker” is a bi- , tri- or tetra-functional chemical moiety which is capable of covalently linking together two to four spaced chemical moieties into a normally stable tri-, tetra or quintapartite molecule, that can release at least one of the spaced chemical moieties from the stable molecule by means of cleavage of a peptide moiety, and following said cleavage, the self-immolative linker can spontaneously cleave from the remainder of the molecule to release the other spaced chemical moiety(ies). An example of this cleavage process discussed in Example 5. Any suitable self-immolative linker may be used in the current invention.
[0122] When used herein, the term “-SELF IMMOLATIVE LINKER-PEPTIDE” is intended to refer to a peptide moiety conjugated to a self-immolative linker by way of a covalent bond. For example, the peptide moiety may be a biomarker reactive moiety.
[0123] In particular embodiments that may be mentioned herein, the compound, or pharmaceutically acceptable salt or solvate thereof, may have formula la. In such embodiments that may be mentioned herein, R may represent:
[0124] where the wiggly line represents the point of attachment to the rest of the molecule; and X represents NEt, O, S or Se, such as O, S or Se, such as S. In further embodiments that may be mentioned herein, R may represent: where the wiggly line represents the point of attachment to the rest of the molecule; and X represents O, S or Se, such as S. In particular embodiments that may be mentioned herein, R4 may be independently selected from: where: the wiggly line represents the point of attachment to the rest of the molecule;
[0125] PEG is PEG1 K, PEG2K, or PEG5K; and n is O to 11.
[0126] In further embodiments that may be mentioned herein, R4 may be independently selected from: where: the wiggly line represents the point of attachment to the rest of the molecule;
[0127] PEG is PEG1 K, PEG2K, or PEG5K; and n is 3 to 5, such as 4.
[0128] In particular embodiments that may be mentioned herein, when present, LINKER may represent:
[0129] , where n is 3 to 5, such as 4, and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the TARGET GROUP.
[0130] In particular embodiments that may be mentioned herein, when present, TARGET GROUP may represent:
[0131] where the wiggly line represents the point of attachment to the rest of the molecule.
[0132] In further embodiments that may be mentioned herein, when present, TARGET GROUP may where the wiggly line represents the point of attachment to the rest of the molecule.
[0133] In particular embodiments that may be mentioned herein, Ri may represent H or I.
[0134] In particular embodiments that may be mentioned herein, R2 may represent H.
[0135] In particular embodiments that may be mentioned herein, R3 may either represent:
[0136] the wavy line represents the point of attachment to the rest of the molecule; or R3may represent -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is: where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule.
[0137] In particular embodiments that may be mentioned herein, R3 may represent -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker may be: where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule. In particular embodiments that may be mentioned herein, when R3 represents -SELF
[0138] IMMOLATIVE LINKER-PEPTIDE, the peptide may be selected from: where the wavy line represents the point of attachment to the rest of the molecule.
[0139] In further embodiments that may be mentioned herein, when R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, the peptide may be: where the wavy line represents the point of attachment to the rest of the molecule.
[0140] As shown above, each of R3 group may represent a biomarker reactive moiety or a biomarker reactive moiety (i.e. a peptide moiety) conjugated to a self-immolative linker. When used herein, the term “radio theranostic moiety” is intended to refer to a substituent group that does not emit radio afterglow and radiodynamic signals due to the presence of a biomarker reactive moiety or a biomarker reactive moiety conjugated to a self-immolative linker by way of a covalent bond, but which is capable of emitting radio afterglow and radiodynamic signals following cleavage of said covalent bond. In other words, the compounds of formula la and lb contain a radio theranostic moiety that initially does not emit radio afterglow and radiodynamic signals because the radio theranostic moiety is in a “caged” state due to a covalent bond reducing the donation of electrons to the radio theranostic moiety system. In the presence of a suitable biomarker, the relevant covalent bond is cleaved (i.e. the covalent bond to the peptide moiety when bonded to it directly or the covalent bond to the self-immolative linker when bonded to this directly), thereby providing a free radio theranostic moiety. This cleavage “uncages” the radio theranostic moiety and results in increased electron donation into the radio theranostic moiety system, thus making the radio theranostic moiety emit radio afterglow and radiodynamic signals. Therefore, the compounds of formula la and lb, are able to selectively activate radio afterglow signals in the presence of a biomarker reactive moiety that is indicative of cancer. As will be appreciated, the biomarkers referred to herein are intended to be ones that may be upregulated in cancer cells. Such biomarkers may include enzymes, reactive oxygen species and reactive nitrogen species (RNS). It will be appreciated that other biomarker reactive moieties other than those disclosed herein may be used in the compounds of formula la and formula lb and so the compounds of formula la and formula lb are not exclusively limited to the biomarker reactive moieties disclosed herein.
[0141] In particular embodiments that may be mentioned herein,
[0142] Ri may be I;
[0143] R2 may be H;
[0144] R may be: the wavy line represents the point of attachment to the rest of the molecule;
[0145] R4 may be where LINKER may be n may be 4;
[0146] PEG may be PEG2K;
[0147] Target Group may the wiggly line represents the point of attachment to the rest of the molecule; Rs may be -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is
[0148] , where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptide the wavy line represents the point of attachment to the rest of the molecule.
[0149] In a second aspect of the invention, there is provided a method for detection of cancer in vivo, the method comprising the following steps:
[0150] (ai) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention to a subject; and
[0151] (aii) detecting any chemiluminescence, wherein the presence of cancer in vivo is indicated by chemiluminescence.
[0152] In embodiments of the invention, the second aspect may further comprise treating the subject for cancer if this is detected. Any possible cancer therapy may be used according to the prognosis and discretion of the attending physician, including the therapy described in the third aspect of the invention below.
[0153] The second aspect of the invention may also be expressed as a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention for use in the detection of cancer in vivo. Where the compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof is administered to a subject and detecting any chemiluminescence, wherein the presence of cancer in vivo is indicated by chemiluminescence. Further, the second aspect of the invention may be expressed as use of a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention for use in the preparation of a medicament for detecting cancer. Where the compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof is to be administered to a subject and detecting any chemiluminescence, wherein the presence of cancer in vivo is indicated by chemiluminescence.
[0154] As will be appreciated, in this detection of cancer, the compounds of formula la or lb, or pharmaceutically acceptable salts or solvates thereof are chosen to provide self-illuminating signal in vivo (e.g. due to the untrapping of a chemiliminescent moiety in the body).
[0155] When used herein, the term “self illuminating signal” is intended to include radio afterglow signals and chemiluminescence.
[0156] In a third aspect of the invention, there is provided a method of treating cancer, the method comprising the following steps:
[0157] (bi) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention to a subject; and
[0158] (bii) subjecting the subject to X-ray irradiation.
[0159] As will be appreciated, the X-ray irradiation may be helpfully targeted to areas that display chemiluminescence when the compounds of formula la or lb, or pharmaceutically acceptable salts or solvates thereof are selected to provide chemiluminescence in vivo. However, this is only a desirable characteristic and is not needed for the treatment to work.
[0160] In addition, it is noted that X-ray irradiation has two properties: i) X-ray induced afterglow imaging through singlet oxygen generation; ii) ii) X-ray activated therapy through reactive oxygen species (ROS).
[0161] The third aspect of the invention may also be expressed as a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention for use in the treatment of cancer. Where the compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof is administered to a subject and the subject is then subjected to X-ray irradiation.
[0162] Further, the third aspect of the invention may be expressed as use of a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to the first aspect of the invention for use in the preparation of a medicament for treating cancer. Where the compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof is to be administered to a subject and the subject is then subjected to X-ray irradiation.
[0163] In some embodiments that may be mentioned herein, the compound of formula la or formula lb, or salt or solvate thereof, may be a compound in which R4 is
[0164] \z°\
[0165] - LINKER -PEG-TARGET GROUP
[0166] Compounds of formula la and formula lb may be administered by any suitable route, but may particularly be administered orally, intravenously, intramuscularly, cutaneously, subcutaneously, transmucosally (e.g. sublingually or buccally), rectally, transdermally, nasally, pulmonarily (e g. tracheally or bronchially), topically, by any other parenteral route, in the form of a pharmaceutical preparation comprising the compound in a pharmaceutically acceptable dosage form. Particular modes of administration that may be mentioned include oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal administration.
[0167] Compounds of formula la and formula lb will generally be administered as a pharmaceutical formulation in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which may be selected with due regard to the intended route of administration and standard pharmaceutical practice. Such pharmaceutically acceptable carriers may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use. Suitable pharmaceutical formulations may be found in, for example, Remington The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995). For parenteral administration, a parenterally acceptable aqueous solution may be employed, which is pyrogen free and has requisite pH, isotonicity, and stability. Suitable solutions will be well known to the skilled person, with numerous methods being described in the literature. A brief review of methods of drug delivery may also be found in e.g. Langer, Science (1990) 249, 1527.
[0168] Otherwise, the preparation of suitable formulations may be achieved routinely by the skilled person using routine techniques and / or in accordance with standard and / or accepted pharmaceutical practice.
[0169] The amount of compound of formula la or formula lb in any pharmaceutical formulation used in accordance with the present invention will depend on various factors, such as the condition to be diagnosed, the particular patient that is the subject of the diagnosis, as well as the compound(s) which is / are employed. In any event, the amount of compound of formula la or formula lb in the formulation may be determined routinely by the skilled person.
[0170] For example, a solid oral composition such as a tablet or capsule may contain from 1 to 99 % (w / w) diagnostic ingredient; from 0 to 99% (w / w) diluent or filler; from 0 to 20% (w / w) of a disintegrant; from 0 to 5% (w / w) of a lubricant; from 0 to 5% (w / w) of a flow aid; from 0 to 50% (w / w) of a granulating agent or binder; from 0 to 5% (w / w) of an antioxidant; and from 0 to 5% (w / w) of a pigment. A controlled release tablet may in addition contain from 0 to 90 % (w / w) of a release-controlling polymer.
[0171] A parenteral formulation (such as a solution or suspension for injection or a solution for infusion) may contain from 1 to 50 % (w / w) diagnostic ingredient; and from 50% (w / w) to 99% (w / w) of a liquid or semisolid carrier or vehicle (e.g. a solvent such as water); and 0-20% (w / w) of one or more other excipients such as buffering agents, antioxidants, suspension stabilisers, tonicity adjusting agents and preservatives.
[0172] Depending on the condition to be diagnosed, and the patient to be diagnosed, as well as the route of administration, compounds of formula la or formula lb may be administered at varying diagnostically effective doses to a subject in need thereof.
[0173] However, the dose administered to a mammal, particularly a human, in the context of the current invention should be sufficient to effect a therapeutic response in the mammal over a reasonable timeframe. One skilled in the art will recognise that the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by inter alia the pharmacological properties of the formulation, the nature and severity of the condition being diagnosed, and the physical condition and mental acuity of the recipient, as well as the properties of the specific compound, the age, condition, body weight, sex and response of the patient to be diagnosed, and the suspected stage / severity of the disease.
[0174] Administration may be continuous or intermittent (e.g. by bolus injection). The dosage may also be determined by the timing and frequency of administration. In the case of oral or parenteral administration the dosage can vary from about 0.01 mg to about 1000 mg per day of a compound of formula la or formula lb.
[0175] In any event, the medical practitioner, or other skilled person, will be able to determine routinely the actual dosage, which will be most suitable for an individual subject. The above- mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
[0176] The term “cancer” will be understood by those skilled in the art to include conditions such as, but not limited to, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain tumours, CNS tumours, breast cancer, Castleman disease, cervical cancer, colon cancer, rectum cancer, endometrial cancer, esophagus cancer, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, kidney cancer, laryngeal cancer, hypopharyngeal cancer, leukemia (e g. acute lymphocytic, acute myeloid, chronic lymphocytic, chronic myeloid, chronic myelomonocytic), liver cancer, lung cancer (e.g. small cell or nonsmall cell), lung carcinoid tumour, lymphoma (e g. of the skin), malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity cancer, paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumours, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer (basal and squamous cell, melanoma, Merkel cell), small intestine cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, and Wilms tumour.
[0177] Particular cancers that may be mentioned herein may be in the form of solid tumours (such as adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain tumours, CNS tumours, breast cancer, Castleman disease, cervical cancer, colon cancer, rectum cancer, endometrial cancer, esophagus cancer, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, kidney cancer, laryngeal cancer, hypopharyngeal cancer, liver cancer, lung cancer (e.g. small cell or non-small cell), lung carcinoid tumour, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity cancer, paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumours, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer (basal and squamous cell, melanoma, Merkel cell), small intestine cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, and Wilms tumour). In particular embodiments that may be mentioned herein, the cancer may be one or more of the following: brain cancer, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, CNS tumours, breast cancer, Castleman disease, cervical cancer, colon cancer, rectum cancer, endometrial cancer, esophagus cancer, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, kidney cancer, laryngeal cancer, hypopharyngeal cancer, liver cancer, lung cancer, lung carcinoid tumour, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal cavity cancer, paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumours, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer (basal and squamous cell, melanoma, Merkel cell), small intestine cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer.
[0178] For the avoidance of doubt, in the context of the present invention, the term “treatment includes references to therapeutic or palliative treatment of patients in need of such treatment, as well as to the prophylactic treatment and / or diagnosis of patients which are susceptible to the relevant disease states.
[0179] The terms “patient’ and “patients” include references to mammalian (e g. human) patients. As used herein the terms "subject" or "patient" are well-recognized in the art, and, are used interchangeably herein to refer to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some embodiments, the subject is a subject in need of treatment or a subject with a disease or disorder. However, in other embodiments, the subject can be a normal subject. The term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are intended to be covered.
[0180] The term “effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated patient (e.g. sufficient to treat or prevent the disease). The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect).
[0181] Further aspects and embodiments of the invention will now be discussed by reference to the following non-limiting examples. Examples
[0182] Materials
[0183] The chemicals were purchased from Sigma-Aldrich, TCI and BLDpharm without further purification. All the deuterated solvents (dimethyl sulfoxide-d6 (DMSO-de), CDCh and CD3OD) were ordered from Cambridge Isotope Laboratories. ESR spin-trapping agent (2, 2,6,6- tetramethylpiperidine (TEMP)) was purchased from Sigma-Aldrich. Cyclic arginine-glycine- aspartate (cRGD) peptide and CatB inhibitor (CA-074) were obtained from MedChemExpress. ROS sensors (SOSG, DHR123 and HPF) were purchased from Thermo Fisher Scientific or Sigma-Aldrich. Enzymes ALP, p-Gal, NTR, GGT and CatB were purchased from Sigma- Aldrich, whereas APN, furin and uPA were purchased from R&D Systems. Anti-cleaved caspase-3 antibody, anti-caspase- 1 antibody and Alexa Fluor 594 secondary antibody were purchased from Abeam and Affbiotech. 4' ,6-Diamidino-2-phenylindole (DAPI), TUNEL assay and H&E were purchased from Servicebio or Abeam company. Cell Counting Kit-8 was ordered from Dojindo Molecular Technologies.
[0184] Ethical requirements
[0185] All the animal experimental procedures were conducted according to the guidelines of the Regional Ethics Committee for Animal Experiments and the Care Regulations approved by the Institutional Animal Care and Use Committee of Fuzhou University. According to the guidelines, mice were sacrificed when the largest tumour size limit is 1.5 cm (at the largest dimension) or 2,000 mm3(for a subcutaneous tumour model) or a weight loss of 20% (for an orthotopic tumour model).
[0186] General procedure for the preparation of the stock solution
[0187] DPAx and IDPAx (X = N, O, Su and Se) and the activatable probes (MRAP and cRGD-free MRAP) were stocked in 0.01 M PBS (pH 7.4, 50% DMSO) at room temperature. The enzymes (ALP, p-gal, furin, NTR, GGT, CatB, APN and uPA) were stocked in distilled water at -80 °C.
[0188] The1H and13C NMR spectra were measured with a Bruker BBFO1 400 nuclear magnetic resonance instrument.
[0189] Liquid chromatography-mass spectrometry (LC-MS) and high-resolution mass spectrometry (HR-MS) Liquid chromatography-mass spectrometry and high-resolution mass spectrometry spectra were conducted on a Thermo Scientific LTQ XL MS and Waters Xevo G2-X2 MS instruments, respectively.
[0190] MALDI time-of-flight mass spectrometry (TOF-MS)
[0191] MALDI TOF-MS analyses were performed on a Broker ultraflex TOF / TOF instrument.
[0192] High-performance liquid chromatography (HPLC) purification and analyses
[0193] HPLC purification and analyses were performed with an Agilent 1260 system using methanol / H2O or acetonitrile / H2O as an eluent. X-ray irradiation was conducted with MOXTEK MAGPRO (Moxtek, Inc. 452 West 1260 North Orem, UT 84057) and the dose was calibrated by RAYSAFE R / F X2 X (FLUKE, USA). White-light irradiation was used by a xenon lamp PLS- SEX300D (Beijing Perfectlight Technology Co., Ltd.).
[0194] Absorption and fluorescence spectroscopy
[0195] The absorption and fluorescence spectra were recorded with a GEN ESYS 50 (Thermo Fisher Scientific) and Cary Eclipse fluorescence spectrophotometer (Agilent Technologies), respectively.
[0196] Electron paramagnetic resonance (EPR) spectroscopy
[0197] EPR spectroscopy was conducted with a Bruker A300 ESR spectrometer (Billerica, MA, USA).
[0198] Radio afterglow and bioluminescence imaging
[0199] Radio afterglow and bioluminescence imaging were recorded with an IVIS spectrum imaging system (IVIS Lumina XRMS, PerkinElmer).
[0200] Procedure for cell assays and cell viability
[0201] All the cells were purchased from the American Type Culture Collection, including CatB- negative cells (mouse embryonic fibroblasts 3T3 cells, RAW 264.7, 293-T and human monocytic TH P-1 cells) and CatB-positive cells (human U87 glioblastoma cells, U87-luciferase cells, A549 lung epithelial cells and 4T1 and melanoma B16-F10). All the cells were cultured in Dulbecco’ s modified Eagle medium (Gibco) or RPMI 1640 medium containing 10.0% foetal bovine serum (Gibco) and 0.1 % ciprofloxacin in a humidified atmosphere containing 5.0% CO2 and 95.0% air at 37 °C. To study the cell viability of IDPAsu, U87 cells (1 x 104 per well) were seeded on 96-well plates and incubated for 24 h. IDPAsu at different concentrations (0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100.0 M) were added to the U87 cell medium for 12 h incubation. After incubation, 96-well plates were covered with chicken breast tissues with different thicknesses (0, 5, 8 and 15 cm), followed by X-ray irradiation. The X-ray setup was optimized to ensure the cells in all the wells received similar dose of X-ray irradiation (2 Gy) before chicken breast tissue coverage (0 cm). After irradiation, the cells were further incubated for 12 h, followed by the colorimetric Cell Counting Kit-8 assay. Briefly, Cell Counting Kit-8 solution (10 pl, Dojindo Molecular Technologies) was added into the cell medium (100 pl) for 2 h incubation, and the absorbance of medium at 450 nm was recorded using a microplate reader (ReadMax 1900). The cells without IDPAsu incubation and X-ray irradiation were set as control. The cell viability (%) was calculated by the absorbance of treated cells over that of the control cells. To test the cell viability of activatable MRAP, U87 and 3T3 cells (1 x 104per well) were seeded on 96-well plates and incubated for 24 h. The inhibitor group was pretreated with a CatB inhibitor (CA-074, 1 mM) for 10 h incubation. MRAP at different concentrations (0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100.0 pM) were added to the U87 and 3T3 cell medium for 12 h incubation. The subsequent steps were similar to the measurement of cell viability of IDPASu. Other CatB-positive and CatB-negative cells were conducted with the same protocol.
[0202] The cell viability was examined with ReadMax 1900 and infinite M200 PRO (TECAN).
[0203] Statistics and reproducibility
[0204] The results in all the experiments were presented as mean ± standard deviation (s.d.) (n > 3). All the radio afterglow and bioluminescence signals were quantified with the region-of-interest analysis using Living Image 4.3 software. The tumour area and immunofluorescence and SOSG intensities were quantified using Imaged v1.51a software. Investigators were blinded to group allocation during the experiments. Statistical calculation of experimental data was analysed using the one-way analysis of variance with a Tukey post-hoc test (more than three independent groups) or a two-tailed Student’s f-test (two independent groups) after normality and equal variance tests. The p values (<0.05) were considered statistically significant: *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p < 0.0001. A statistical analysis was performed using Origin 2021 or GraphPad Prism 8.0 software.
[0205] Example 1. Synthesis of organic luminophores
[0206] The radio afterglow dynamic luminophores were synthesized based on the acceptor-phenoxy- adamantylidene scaffold via a convergent approach (Fig. 1). First, the acceptors including dicyanomethylene-4H-quinoline (DBQ), dicyanomethylene-4H-benzopyran (DBP), dicyanomethylene-4H-benzothiopyran (DBTP) and dicyanomethylene-4H-benzoselenopyran (DBSeP) were synthesized (Figs. 1b-e). Then, these acceptors were linked to phenoxy- adamantylidene with or without the heavy atom (iodine), respectively, leading to DBQ- phenoxy-adamantylidene (DPAN), DBP-phenoxy-adamantylidene (DPAo), DBTP-phenoxy- adamantylidene (DPAsu), DBSeP-phenoxy-adamantylidene (DPAse) and the corresponding iodine-containing counterparts, namely, IDPAx (X = N, O, Su and Se) (Fig. 1a). All the compounds were confirmed by nuclear magnetic resonance and liquid chromatography- mass spectrometry.
[0207] Synthesis of compound 2
[0208] The phenol-adamantylidene derivative compound 1 was successfully synthesized according to previous literature (Gnaim, S. & Shabat, D., J. Am. Chem. Soc. 2017, 139, 10002-10008). The sodium borohydride (0.755 g, 20 mmol) was added portionwise over a period of 10 min to a solution of compound 1 (1.49 g, 5 mmol) in MeOH (20 ml) and stirred for 30 min at room temperature. After completing the reaction by thin layer chromatography (TLC) monitoring, the reaction mixture was concentrated in vacuo to remove methanol and extracted with ethyl acetate (EtOAc, 3 * 50 ml) and brine (3 x 50 ml). The organic layer was dried on anhydrous Na2SC>4. The residue was obtained in vacuo and purified by flash column chromatography to give a white solid compound 2 (1.5 g, 100% yield).
[0209] 1H NMR (400 MHz, CDCI3): 5 7.28 (d, J = 2 Hz, 1 H), 6.77 (dd, J = 2.8, 8.4 Hz, 1 H), 6.71 (d, J = 2.8 Hz, 1 H), 4.30-4.81 (m, 2H), 3.32 (s, 3H), 3.28 (s, 1H), 2.28 (s, 1 H), 1.72-1.99 (m, 12H).13C NMR (101 MHz, CDC ): 6 155.3, 141.8, 136.3, 133.8, 132.3, 131.0, 118.2, 115.2, 64.1 , 57.8, 50.9, 39.3, 37.1 , 32.6, 29.9, 28.4. MS (ESI ): m / z = 299.1 [M-H .
[0210] Synthesis of compound 3
[0211] To a solution of compound 2 (1.2 g, 4 mmol) and NaOH (240 mg, 6 mmol) in MeOH (25 ml) was added dropwise ICI (649 mg, 4 mmol) at 0 °C and stirred for 1 h. Upon completing the reaction, the mixture was quenched with saturated Na2S20s (30 ml) and stirred for 10 min. The methanol was removed in vacuo and the residue was extracted with EtOAc (3 x 50 ml) and saturated NH4CI (2 x 100 ml). The organic phase was collected and dried with anhydrous Na2SO4, followed by concentration. The residue was purified by column chromatography on silica gel using hexane / EtOAc as the eluent to afford compound 3 (1.28 g, 75% yield) as a white solid.
[0212] 1H NMR (400 MHz, CDCh): 6 7.74 (s, 1 H), 6.80 (s, 1 H), 5.6 (s, 1 H, OH), 4.50 (br, 2H), 3.29 (s, 3H), 3.24 (s, 1 H), 2.25 (s, 1 H), 1.77-1.96 (m, 12H).13C NMR (101 MHz, CDCh): 6 179.3, 154.1 , 141.1 , 139.0, 136.8, 134.9, 134.4, 117.5, 85.1 , 63.3, 57.8, 39.3, 37.1 , 32.7, 29.8, 28.3.
[0213] MS (ESI ): m / z = 425.1 [M-H]-.
[0214] To a solution of compound 3 (825.1 mg, 2 mmol), silica gel (1 g) and pyridine (403 pl, 5 mmol) in anhydrous dichloromethane (20 ml) was added dropwise pyridinium dichromate (1128.6 mg, 3 mmol) at 0 °C and stirred for 3 h. Upon completing the reaction, the silica gel solid was filtered and the filtrate was washed with saturated NH4CI (2 x 100 ml) and dichloromethane (2 x 100 ml). The organic layer was dried with anhydrous Na2SC>4, and evaporated in vacuo which was further purified with silica gel chromatography using hexane / EtOAc to give a white solid compound 4 (577 mg, 68% yield).
[0215] 1H NMR (400 MHz, CDCh): 5 10.03 (s, 1 H), 8.32 (s, 1H), 6.91 (s, 1 H), 3.30 (s, 4H), 2.25 (s, 1H), 1.74-1.97 (m, 12H).13C NMR (101 MHz, CDCh): 6 190.1 , 159.1 , 142.1, 138.5, 138.0, 135.6, 130.1 , 117.1 , 85.3, 57.6, 39.1 , 39.1 , 37.0, 32.8, 30.1 , 28.2. MS (ESI ): m / z = 424.1 [M- H]-.
[0216] To a solution of 2-methylquinoline (1430 mg, 10 mmol) in ACN (2 ml) was added iodoethane (1206 pl, 15 mmol) at room temperature and stirred overnight at 80 °C under N2 atmosphere. The reaction mixture was filtered to obtain yellow crude solid which was washed with cold diethyl ether (3 x 100 ml) to give compound 5 (2.42 g, 85% yield).1H NMR (400 MHz, CD3OD): 5 9.01 (d, J = 8.4 Hz, 1 H), 8.58 (d, J = 8.8 Hz, 1 H), 8.37 (d, J = 8.4 Hz, 1 H), 7.99 (d, J = 8.4 Hz, 1 H), 5.09 q, J = 7.3 Hz, 2H), 3.17 (s, 3H), 1.68 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, CD3OD): 6 161.6, 147.3, 140.1 , 136.8, 132.0, 130.4, 126.6, 119.7, 22.9, 13.9. MS (ESI+): m / z 172.1 [M-l]+.
[0217] Synthesis of compound DBQP
[0218] Sodium (92 mg, 4 mmol) was added dropwise to a solution of compound 5 (570 mg, 2 mmol) and malononitrile (528.2 mg, 8 mmol) in anhydrous ethanol (10 ml) and stirred for 10 h at an ice bath. The reaction mixture was concentrated in vacuo to remove ethanol to obtain the crude product. The residue was washed by DI water (3 x 30 ml) and EtOAc (3 x 30 ml) and dried at 50 °C in vacuo to give the pure DBQP (157 mg, 71%) as a yellow solid.
[0219] 1H NMR (400 MHz, CDCI3): 6 9.00 (dd, J = 1.6, 8.8 Hz, 1 H), 7.72-7.76 (m, 1 H), 7.62 (d, J = 8.4 Hz, 1H), 7.37-7.41 (m, 1 H), 6.74 (s, 1 H), 4.35 (q, J = 7.3 Hz, 2H), 2.58 (s, 3H), 1.48 (t, J =
[0220] 7.2 Hz, 3H).13C NMR (101 MHz, CDCI3): 6 153.6, 147.7, 138.2, 133.3, 126.9, 124.7, 121.6, 120.6, 119.1 , 116.2, 110.0, 43.0, 21.6, 13.8. MS (ESI+): m / z 226.2 [M+H]+.
[0221] Synthesis of compounds D
[0222] General method: the mixture of acceptor dicyanomethylene-4H derivative (0.06 mmol), piperidine (0.02 mmol), and phenol-adamantylidene derivative (compound 1 or compound 4) (0.05 mmol) were dissolved in anhydrous ACN (2.5 ml) and refluxed for 2-8 h under N2 atmosphere. After completing reaction, the mixture was extracted with brine (2 x 20 ml) and dichloromethane (2 x 20 ml), and then the organic solution was collected and dried over anhydrous Na2SO4. The organic solvent was removed in vacuo to give the crude product. The crude product was further purified by HPLC using methanol and water as an eluent to afford corresponding products.
[0223] Compound DPAN (24 mg, 92% yield) was obtained as a yellow solid.1H NMR (400 MHz, DMSO-de): 6 8.91 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.79-7.95 (m, 2H), 7.60 (d, J = 8.4 Hz, 1 H), 7.39 (dd, J = 42.4, 16 Hz, 2H), 6.97 (s, 1 H), 6.88 (dd, J = 8.4, 2 Hz, 1 H), 6.67 (d, J = 6.4 Hz, 1 H), 4.56 (q, J = 5.4 Hz, 2H), 3.21 (s, 1 H), 3.19 (s, 3H), 2.11 (s, 1 H), 1.70-1.91 (m, 12H), 1.48 (t, J = 7.0 Hz, 3H).13C NMR (101 MHz, DMSO-ds): 6 158.8, 152.2, 149.7, 140.6, 137.9, 137.7, 137.2, 133.7, 130.6, 128.5, 125.3, 125.1, 124.9, 120.6, 118.1 , 117.6, 117.3, 116.0, 106.1, 56.3, 46.6, 43.7, 36.5, 32.2, 29.0, 27.6, 13.7. MS (ESP): m / z 514.2 [M-H]-.
[0224] Compound IDPAN (27.9 mg, 87% yield) was obtained as a yellow solid.
[0225] 1H NMR (400 MHz, DMSO-d6): 5 10.92 (s, -OH, 1 H), 8.92 (d, J = 8.4 Hz, 1 H), 8.43 (s, 1 H), 8.09 (d, J = 8.8 Hz, 1 H), 7.93 (d, J = 7.2 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1 H), 7.46 (d, J = 16 Hz, 1H), 7.31 (d, J = 15.6 Hz, 1 H), 6.94 (s, 1 H), 6.77 (s, 1 H), 4.59 (dd, J = 14, 7.2 Hz, 1 H), 3.18 (m, 3H), 2.12 (s, 1H), 1.63-1.95 (m, 12H), 1.38 (t, J= 7.0 Hz, 3H).13C NMR (101 MHz, DMSO- d6): 6 157.8, 152.2, 149.6, 140.1 , 137.9, 137.1, 136.9, 136.2, 133.7, 131.2, 127.3, 125.0, 120.7, 119.0, 118.2, 116.5, 106.4, 56.4, 46.8, 43.7, 36.4, 32.3, 31.3, 29.0, 13.7. MS (ESI’): m / z 640.3 [M-H]-.
[0226] To a solution of 2-hydroxyacetophenone (10 g, 73 mmol) in anhydrous EtOAc (80 ml) was added dropwise sodium hydride (7 g, 184 mmol, 60 % dispersion in mineral oil) at room temperature and stirred overnight at 80 °C. Then, cold HCI (50 ml) (1 N) was added to quench the reaction and the organic layer was collected, dried with anhydrous Na2SO4 and evaporated in vacuo to obtain the crude diketone product. Several drops of concentrated HCI were added to a solution of the crude diketone in methanol (50 ml) and stirred for 14 h. The mixture was concentrated to remove methanol in vacuo, extracted with EtOAc (3 x 100 ml) and brine (3 x 100 ml). The organic layer was dried with anhydrous Na2SO4, evaporated in vacuo and purified with silica gel chromatography using hexane / EtOAc to give compound 6 as a white solid (7.59 g, 65% yield).1H NMR (CDCh, 400 MHz): 6 8.16 (d, J = 7.6 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1 H), 7.34-7.40 (m, 2H), 6.16 (s, 1H), 2.37 (s, 3H).13C NMR (101 MHz, CDCh): 6 178.4, 166.3, 156.6, 133.6, 125.7, 125.0, 123.7, 117.9, 110.7, 20.7. MS (ESP): m / z = 161.1 [M+H]+.
[0227] The mixture of compound 6 (4 g, 25 mmol) and malononitrile (3.3 g, 50 mmol) were dissolved in acetic anhydride (40 ml). The reaction mixture was stirred vigorously and refluxed for 6 h. After completion of the reaction, the mixture was concentrated in vacuo to remove acetic anhydride and extracted with saturated NaHCCh (3 x 200 ml) and EtOAc (3 x 200 ml). The organic layer was collected and dried with anhydrous Na2SO4 to obtain the residue which was purified with silica gel chromatography using hexane / EtOAc to give a brownish yellow solid (3.7 g, 71% yield).
[0228] 1H NMR (CDCh, 400 MHz): 6 8.90 (d, J = 8.4 Hz, 1 H), 7.69-7.75 (m, 1 H), 7.42-7.48 (m, 2H), 6.71 (s, 1 H), 2.44 (s, 3H).13C NMR (101 MHz, CDCh): 6 178.4, 166.3, 156.6, 133.6, 125.7, 125.0, 123.7, 117.9, 110.7, 20.7. MS (ESP): m / z = 209.2 [M+H]+.
[0229] Synthesis of compounds
[0230] The reaction procedure is similar to the synthesis of DPAN and IDPAN above. The product yield was determined by HPLC analysis.
[0231] Compound DPAo (19.8 mg, 81% yield) was obtained as a yellow solid.
[0232] 1H NMR (400 MHz, CDCh): 6 8.90 (d, J = 8.0 Hz, 1 H), 7.93 (d, J = 16 Hz, 1 H), 7.67-7.74 (m, 2H), 7.42-7.46 (m, 2H), 6.92 (d, J = 7.6 Hz, 1 H), 6.81 (s, 2H), 6.69 (d, J = 16 Hz, 1 H), 6.67 (d, J = 6.4 Hz, 1 H), 3.38 (s, 1 H), 3.30 (s, 3H), 2.14 (s, 1 H), 1.71-1.97 (m, 12H).13C NMR (101 MHz, CDCh): 6 158.4, 158.0, 153.3, 152.5, 139.7, 138.8, 137.5, 134.8, 132.8, 127.8, 127.0, 126.9, 126.0, 125.9, 120.1 , 118.6, 118.0, 117.9, 116.6, 116.4, 106.5, 57.2, 37.1 , 32.8, 30.0,
[0233] 28.4. MS (ESI ): m / z = 487.2 [M-H]-. Compound IDPAo (20.6 mg, 67% yield) was obtained as an orange solid.
[0234] 1H NMR (400 MHz, DMSO-de): 5 8.72 (dd, J = 8.4, 1.2 Hz, 1 H), 8.39 (s, 1 H), 7.89-7.91 (m, 1H), 7.7 (d, J = 16 Hz, 1 H), 7.59 (m, 1H), 7.49 (d, J = 7.6 Hz, 1 H), 7.44 (d, J = 16 Hz, 1H), 6.99 (s, 1H), 6.78 (s, 1H), 3.21 (s, 3H), 1.64-2.02 (m, 13H).13C NMR (101 MHz, DMSO-de): 6 158.4, 158.3, 152.8, 151.8, 139.4, 137.6, 136.7, 135.6, 134.8, 131.0, 127.2, 126.2, 124.8, 118.3, 117.6, 117.2, 116.2, 115.8, 106.5, 86.3, 60.0, 56.5, 36.4, 32.2, 29.2, 27.6. MS (ESP): m / z = 613.2 [M-H]-.
[0235] Synthesis of compound 7
[0236] 7
[0237] A mixture of benzenethiol (2.2 g, 20 mmol) and ethyl 3-oxobutanoate (2.86 g, 22 mmol) was added to polyphosphoric acid (24 ml) at 90 °C and stirred for 30 min. Then, the cooled mixture was quenched with ice water and extracted with EtOAc (3 x 50 ml) for three times. The organic solution was combined, dried over anhydrous Na2SC>4, and evaporated under vacuum. The crude product was purified by silica gel chromatography using hexane / EtOAc as an eluent to give compound 7 as a yellow solid (2.39 g, 68% yield).
[0238] 1H NMR (400 MHz, CDCI3): 3 8.49 (m, 1 H), 7.52 - 7.59 (m, 2H), 7.47-7.51 (m, 1 H), 6.83 (d, J = 0.8 Hz, 1H), 2.45 (d, J = 1.2 Hz, 3H).13C NMR (101 MHz, CDCh): 6 180.7, 151.3, 137.8, 131.5, 130.9, 128.7, 127.6, 126.1 , 125.0, 23.4. MS (ESI+): m / z = 177.1 [M+H]+.
[0239] Synthesis of compound DBTP
[0240] The mixture of compound 7 (500 mg, 2.84 mmol) and malononitrile (1 .5 g, 22.7 mmol) in Ac2O (10 ml) was heated to 140 °C and stirred for 2 h. After completing reaction, methanol (10 ml) was added and stirred at 50 °C for another 2 h. At last, the mixture solvent was evaporated under vacuum. The crude product was purified by silica gel chromatography using hexane / EtOAc as the eluent to give a yellow solid compound DBTP (337 mg, 53% yield).1H NMR (400 MHz, CDCI3): 5 8.95 (d, J = 8 Hz, 1 H), 7.56-7.64 (m, 3H), 7.41 (s,1 H), 2.53 (s, 3H).13C NMR (101 MHz, CDCI3): 6 156.1 , 149.0, 136.2, 131.9, 128.6, 128.5, 127.2, 125.1 , 120.8, 117.1 , 115.8, 23.6. MS (ESI+): m / z = 225.1 [M+H]+.
[0241] Synthesis of compounds D
[0242] The reaction procedure is similar to the synthesis of DPAN and I DPAN above. The product yield was determined by HPLC analysis.
[0243] Compound DPAsu (19.2 mg, 76%) was obtained as an orange solid.
[0244] 1H NMR (400 MHz, CDCI3): 6 8.89 (d, J = 8.4 Hz, 1 H), 7.66 (d, J = 8 Hz, 2H), 7.53-7.63 (m, 3H), 7.50 (s, 2H), 6.91-7.01 (m, 2H), 6.80 (s, 1H), 3.35 (s, 1 H), 3.31 (s, 3H), 2.12 (s, 1 H), 1.69- 1.91 (m, 12H).13C NMR (101 MHz, CDCI3): 6 157.8, 156.2, 148.8, 139.8, 138.3, 136.0, 135.2, 133.1 , 132.0, 128.4, 128.3, 127.7, 127.6, 127.1 , 125.7, 123.4, 121.1, 118.0, 116.3, 67.5, 57.1 , 39.2, 37.1 , 33.5, 32.8, 30.0, 29.8, 29.8, 28.4. MS (ESI’): m / z = 503.2 [M-H]-.
[0245] Compound IDPAsu (19.8 mg, 67%) was obtained as an orange solid.
[0246] 1H NMR (400 MHz, CDCI3): 6 10.99 (s, -OH, 1 H), 8.73 (d, J = 8.4 Hz,1H), 8.42 (s, 1 H), 7.97 (d, J = 16 Hz,1H), 7.76 (t, J = 7 Hz,1 H), 7.67-7.71 (t, J = 7 Hz,1 H), 6.91-7.01 (m, 2H), 7.63 (s, 1H), 7.36 (d, J = 16.4 Hz,1 H), 6.75 (s, 1H), 3.28 (s, 1 H), 3.31 (s, 3H), 2.01 (s, 1H), 1.60-1.81 (m, 12H).13C NMR (101 MHz, CDCI3): 6 158.0, 155.6, 148.2, 139.6, 137.1 , 136.7, 134.1 , 133.2, 132.6, 131.0, 128.4, 128.0, 127.6, 127.3, 124.6, 124.3, 120.9, 117.3, 116.3, 115.8, 86.2, 66.9, 56.4, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1 , 38.9, 38.5, 36.4, 32.2, 29.1 , 27.6. MS (ESI’): m / z = 629.1 [M-H]’.
[0247] Synthesis of compound 8 To a solution of propynylmagnesium bromide (36 ml, 0.5 M solution in THF, 18 mmol) was added o-bromobenzaldehyde (2.76 g, 15 mmol) in anhydrous THF (100 ml) at room temperature and stirred for 1 h. After completing the reaction, the reaction mixture was quenched with saturated aqueous NH4CI (3 * 50 ml), extracted with EtOAc (3 x 50 ml), and the organic layer was collected and dried over anhydrous Na2SO4. The solvent was then evaporated under vacuum to give the crude product which was further purified by silica gel chromatography to give a colorless liquid compound 8 (3.36 g, 100% yield).
[0248] 1H NMR (400 MHz, CDCI3): 6 7.77 (d, J = 1.6 Hz, 1 H), 7.55 (dd, J = 8, 1.6 Hz, 1 H), 7.34-7.38 (m, 1H), 7.18 (m, 1 H), 5.74-5.76 (m, 1H), 2.51 (d, J = 1.2 Hz, 1 H), 1.90 (d, J = 1.2 Hz, 3H).13C NMR (101 MHz, CDCI3): 6 140.1, 133.1 , 129.9, 128.6, 127.9, 122.8, 83.6, 78.2, 77.5, 77.2, 76.8, 64.4, 3.9. MS (ESI+): m / z = 225.2 [M+H]+.
[0249] Synthesis of compound 9
[0250] To a solution of compound 8 (2.24 g, 10 mmol) in DMSO (20 ml), 2-iodoxybenzoic acid (IBX) (3.36 g, 12 mmol) was added slowly at room temperature and stirred for 2 h. The reaction was quenched with water (20 ml) and extracted with EtOAc (20 ml) and brine (30 ml) for three times. The organic layer was combined and dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude product was purified by column chromatography with hexane / EA to afford a colorless liquid compound 9 (2.13 g, 96% yield).
[0251] 1H NMR (400 MHz, CDCI3): 6 7.97 (dd, J = 7.6, 1.6 Hz, 1 H), 7.61 (d, J = 8 Hz, 1 H), 7.37 (t, J = 6.8 Hz, 1 H), 7.30 (m, 1 H), 2.08 (s, 3H).13C NMR (101 MHz, CDCI3): 6 177.5, 137.1, 134.8, 133.2, 133.0, 127.3, 120.9, 93.9, 79.9, 4.4. MS (ESI+): m / z = 223.0 [M+H]+.
[0252] Synthesis of compound 10
[0253] Powder Se (474 mg, 6 mmol) was added to a solution of NaBH4(189 mg, 5 mmol) in anhydrous dimethylformamide (DMF, 5 ml) at room temperature. The mixture was heated to 105 °C and stirred for 1 h. Then the solution of compound 9 (1.11 g, 5 mmol) in dry DMF (8 ml) was added dropwise to the mixture and stirred at 105 °C for another 4 h. After the reaction was cooled to room temperature, the mixture was extracted with EtOAc (20 ml) for three times. The combined organic layers were washed with brine and dried over anhydrous Na2SO4, filtered, and evaporated. The crude product was purified by column chromatography with hexane / EtOAc as the eluent to produce a yellow solid compound 10 (896 mg, 85% yield).
[0254] 1H NMR (400 MHz, CDCI3): 3 8.62-8.64 (d, J = 8.1 Hz, 1 H), 7.64-7.68 (m, 1 H), 7.52-7.59 (m, 2H), 6.98 (d, J = 1.2 Hz, 1 H), 2.59 (d, J = 0.8 Hz, 1 H).13C NMR (101 MHz, CDCI3): 3 182.5, 152.9, 136.8, 131.5, 130.1 , 128.2, 127.7, 127.0, 77.5, 77.2, 76.8, 25.1. MS (ESP): m / z = 224.1 [M+H]+.
[0255] Synthesis of compound DBSeP
[0256] To a solution of compound 10 (500 mg, 2.23 mmol) in AC2O (10 ml) was added malononitrile (1.18 g, 17.8 mmol) and stirred for 2 h at 145 °C. After finishing the reaction, methanol (10 ml) was added and stirred for 2 h when the reaction was cooled down to the room temperature. The solvent was then evaporated by vacuum evaporation. The crude product was purified by silica gel chromatography using hexane / EtOAc as the eluent to give a brown solid DBSeP (188 mg, 31% yield).
[0257] 1H NMR (400 MHz, CDCI3): 3 8.72-8.76 (m, 1 H), 7.68-7.73 (m, 1 H), 7.50-7.56 (m, 3H), 2.60 (d, J = 0.8 Hz, 3H).13C NMR (101 MHz, CDCI3): 3 159.0, 151.3, 135.5, 131.7, 129.9, 129.2, 128.3, 126.2, 122.5, 116.7, 115.4, 25.4. MS (ESP): m / z = 273.0 [M+H]+.
[0258] Synthesis of comp
[0259] The reaction procedure is similar to the synthesis of DPAN and IDPAN above. The product yield was determined by HPLC analysis.
[0260] Compound DPASe(14 mg, 52% yield) was obtained as an orange solid.1H NMR (400 MHz, CDCI3): 6 8.71 (m, 1 H), 7.73 (d, J = 3.6 Hz, 1 H), 7.73 (d, J = 8.4 Hz, 2H), 7.63 (s, 1 H), 7.51-7.53 (m, 2H), 7.43 (d, J = 16 Hz, 1 H), 7.08 (d, J = 16 Hz, 1 H), 6.89 (d, J = 8.4 Hz, 1H), 6.76 (s, 1 H), 3.35 (s, 1H), 3.29 (s, 3H), 2.11 (s, 1 H), 1.69-2.01 (m, 12H).13C NMR (101 MHz, CDCh): 6 159.1, 157.3, 150.6, 140.0, 138.4, 136.8, 134.1 , 132.8, 131.8, 129.7,
[0261] 129.6, 128.2, 127.6, 127.2, 125.6, 123.2, 118.0, 116.3, 57.1 , 39.2, 37.2, 32.8, 30.0, 28.4. MS (ESI ): m / z 551.1 [M-H]-.
[0262] Compound IDPAse (19.8 mg, 38% yield) was obtained as an orange solid.
[0263] 1H NMR (400 MHz, DMSO-de): 6 10.99 (s, -OH, 1 H), 8.58 (dd, J = 7.6, 1.2 Hz, 1 H), 8.42 (s, 1H), 8.12 (dd, J = 8, 1.6 Hz, 1 H), 7.73-7.67 (m, 2H), 7.62-7.67 (m, 2H), 7.21 (d, J= 16 Hz,1H), 6.74 (s, 1 H), 3.27 (s, 1 H), 3.20 (s, 3H), 1.58-2.0 (m, 13H).13C NMR (101 MHz, DMSO-de): 0
[0264] 158.7, 158.0, 150.6, 139.7, 137.0, 136.7, 134.1, 133.2, 132.2, 131.0, 130.2, 129.2, 128.2, 127.5, 126.4, 126.1 , 122.9, 117.0, 116.3, 115.5, 86.2, 71.2, 56.4, 36.4, 32.2, 29.1 , 27.6. MS (ESI ): m / z = 677.0 [M-H]-.
[0265] Synthesis of compounds alkyne-PEG2000-OMe and alkyne-PEG2000-COOH
[0266] The compounds alkyne-PEG2000-OMe and alkyne-PEG2QOO-COOH were successfully synthesized according to previous literature (He, S. etal., J. Am. Chem. Soc. 2020, 742, 7075- 7082).
[0267] Alkyne-PEG2000-OMe was obtained as a white powder.
[0268] 1H NMR (400 MHz, CDCI3): 5 4.20 (d, J = 2.4 Hz, 2H), 3.64-3.69 (m, 176H), 3.54 (dd, J = 2.8 5.2 Hz, 4H), 3.37 (s, 3H), 2.43 (t, J = 2.4 Hz, 1 H). MALDI-TOF-MS: 1500-2500Da. Alkyne- PEG2000-COOH as a white solid was obtained.1H NMR (400 MHz, CDCh): 5 3.96 (s, 2H), 3.44-3.82 (m, 182H), 2.43 (t, J = 2.2 Hz, 1 H). MALDI-TOF-MS: 1400-2600 Da.
[0269] Alkyne-PEG2000-cRGD as a white powder was also obtained.
[0270] A mixture of N-hydroxysuccinimide (17.2 mg, 0.15 mmol), 4-dimethylaminopyridine (18.4 mg, 0.15 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (23.2 mg, 0.15 mmol) was added to a solution of alkyne-PEG2000-CGGH (200 mg, 0.1 mmol) in anhydrous dichloromethane (5 ml) and stirred for 12 h at room temperature. After monitoring the reaction by TLC analysis, the mixture was extracted with saturated NaCI (3 x 20 ml) and dichloromethane (3 x 20 ml). The organic layer was combined, dried in anhydrous Na2SO4 and concentrated in vacuo. The solution of the obtained residue in anhydrous DMF (2 ml) was added to a mixture of cRGD (94.8 mg, 0.1 mmol) and NaHCCh (16.8 mg, 0.1 mmol) in anhydrous DMF (3 ml) and stirred overnight at room temperature. After completing reaction, the mixture was dialyzed against DI water (spectra / pore, MWCO 2 KDa) and then freeze-dried to give alkyne-PEG2000- cRGD (-248 mg, -80% cRGD grafting yield) as a white solid.
[0271] Synthesis of compound 11
[0272] This reaction procedure is similar to the synthesis of compound 7 above. Briefly, 4- methoxybenzenethiol (2.8 g, 20 mmol) and ethyl 3-oxobutanoate (2.86 g, 22 mmol) were added to polyphosphoric acid (24 ml) at 90 °C and stirred for 30 min. Then, the mixture was cooled to room temperature and then worked up. The residue was purified by silica gel chromatography using hexane / EtOAc as an eluent to give compound 11 as a yellow solid (2.8 g, 68% yield).
[0273] 1H NMR (400 MHz, CDCh): 6 7.94 (d, J = 2.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1 H), 7.20 (dd, J = 8.8, 2.8 Hz, 1 H), 6.84 (s, 1 H), 3.91 (s, 3H), 2.46 (s, 3H).13C NMR (101 MHz, CDCh): 6 180.4, 159.5, 151.3, 132.2, 129.8, 127.4, 124.2, 122.0, 109.0, 55.8, 23.3. MS (ESP): m / z = 207.3 [M+H]+.
[0274] Synthesis of compound 12
[0275] To a solution of compound 11 (1030 mg, 5 mmol) in anhydrous dichloromethane (10 ml) was added dropwise BBr3(949 ml, 10 mmol) at 0 °C and stirred for 6 h. The grey solid was precipitated and washed with EtOAc (3 x 50 ml) to give pure compound 12 (912 mg, 95%) as a pale yellow solid.
[0276] 1H NMR (400 MHz, DMSO-d6): 6 10.16 (s, 1 H), 7.68 (d, J = 2.8 Hz, 1 H), 7.64 (d, J = 8.8 Hz, 1H), 7.18 (dd, J = 8.8, 2.8 Hz, 1 H), 6.77 (s, 1 H), 2.44 (s, 3H).13C NMR (101 MHz, DMSO-ds): 6 178.9, 157.3, 151.5, 131.5, 128.1 , 126.8, 123.2, 121.4, 111.8, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9, 22.7. MS (ESh): m / z = 191.2 [M-H]’.
[0277] The mixture of compound 12 (480 mg, 2.5 mmol), K2CO3 (691 mg, 5 mmol) and 1-azido-4- iodobutane (675 mg, 3 mmol) in anhydrous DMF (5 ml) was stirred overnight at 80 °C under N2 atmosphere. The mixture was poured into saturated NH4CI solution (50 ml) and extracted with EtOAc (3 x 100 ml). The organic layers were combined and concentrated in vacuo. Then, the residue was purified with silica gel chromatography using hexane / EtOAc as an eluent to give compound 13 as a yellow solid (2.8 g, 87% yield).
[0278] 1H NMR (400 MHz, CDCh): 0 7.92 (d, J = 2.4 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1 H), 7.20 (dd, J = 8.8, 2.4 Hz, 1 H), 6.84 (s, 1 H), 4.11 (t, J = 6.0 Hz, 2H), 3.37 (t, J = 6.8 Hz, 2H), 2.46 (s, 3H), 1.88-1.95 (m, 2H), 1.77-1.84 (m, 2H).13C NMR (101 MHz, CDCI3): 6 158.8, 151.4, 129.8, 127.5, 124.2, 122.2, 109.8, 77.5, 77.2, 76.8, 67.8, 51.3, 26.5, 25.9, 23.4. MS (ESP): m / z = 312.1 [M+Na]+.
[0279] The reaction procedure of compound 14 is similar to the synthesis of compound 8 above. Compound 14 (303.4 mg, 45% yield) as a yellow solid was obtained by silica gel chromatography using hexane / EtOAc as the eluent.
[0280] 1H NMR (400 MHz, CDCI3): 6 8.44 (s, 1 H), 7.56 (d, J = 8.4 Hz, 1 H), 7.42 (s, 1 H), 7.28 (s, 1 H), 4.15 (t, J = 5.0 Hz, 2H), 3.39 (t, J= 6.0 Hz, 2H), 2.55 (s, 3H), 1.93-1.96 (m, 2H), 1.79-1.86 (m, 2H).13C NMR (101 MHz, CDCI3): 0 158.8, 155.8, 149.0, 128.2, 126.3, 122.8, 120.4, 117.7, 110.3, 68.3, 51.2, 26.4, 25.8, 23.5. (ESP): m / z = 338.2 [M+H]+.
[0281] To a solution of compound 14 (67.4 mg, 0.2 mmol) and compound 4 (127.2 mg, 0.3 mmol) in anhydrous I (4 ml) was added piperidine (20 ml, ~0.2 mmol) under N2atmosphere and stirred at 90 °C for 2 h. The product compound 15 (136.7 mg, 92% yield) as an orange solid was purified by HPLC using ACN / water as eluent.
[0282] 1H NMR (400 MHz, CDCI3): 6 8.40 (d, J = 2.4 Hz, 1 H), 8.08 (s, 1 H), 7.58 (d, J = 8.8 Hz, 1 H), 7.55 (s, 1 H), 7.45 (d, J = 16.4 Hz, 1 H), 7.24 (d, 2.4 Hz, 1 H), 7.00 (d, J = 16.4 Hz, 1H), 6.90
[0283] (s, 1 H), 4.14 (t, J = 6.0 Hz, 2H), 3.38 (t, =2.4 Hz, 2H), 3.34 (s, 1 H), 3.29 (s, 3H), 2.13 (s, 1H), 1.88-2.01 (m, 12H), 1.68-1.76 (m, 4H).13C NMR (101 MHz, CDCI3): 6 158.8, 156.0, 155.8, 147.9, 139.5, 138.7, 136.0, 133.7, 133.6, 129.5, 128.7, 127.0, 124.7, 122.9, 121.5, 117.4, 110.4, 86.3, 68.3, 57.3, 51.3, 39.2, 37.1 , 32.9, 31.6, 30.4, 30.0, 29.8, 28.4, 26.4, 25.8. (ESI ): m / z 742.2 [M-H]’.
[0284] The mixture of CuSO4- 5H2O (0.62 mg, 0.0025 mmol) and ascorbic acid sodium (2.47 mg, 0.0125 mmol) in DI water (0.4 ml) was added to a solution of compound 15 (37.2 mg, 0.05 mmol) and alkyne-PEG2000-cRGD (124.1 mg, 0.05 mmol, - 80% cRGD grafting yield) in DMSO (4 ml) under N2atmosphere and stirred at room temperature for 4 h. After completing the reaction, the mixture was dialyzed against DI water (spectra / pore, MWCO 2 KDa) and then freeze-dried to give uncaged MRAP (153 mg, 95% product yield after click reaction and - 80% cRGD grafting yield) as an orange powder.
[0285] 1H NMR (400 MHz, DMSO-d6): 6 8.42 (s, 1 H), 8.10 (s, 1 H), 7.92 (d, J = 8.8 Hz, 1 H), 7.66 (d, J = 7.2 Hz, 1 H), 7.61 (s, 1 H), 7.41-7.45 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H), 7.18-7.26 (m, 4H), 6.73 (s, 1H), 4.51 (s, 1.6H), 4.41-4.44 (m, 2H), 4.43-4.44 (m, 1 H), 4.13-4.14 (m, 4H), 3.85- 3.87 (m, 1.6H), 3.86 (d, J = 7.6 Hz, 2H), 3.40-3.68 (m, 180H), 3.25-3.28 (m, 3H + 3.2H), 3.20 (s, 3H), 2.94-3.09 (m, 4H), 2.67-2.80 (m, 1.6H), 1.78-2.01 (m, 13H), 1.59-1.74 (m, 8H).
[0286] Synthesis of compound Z-Val-Cit
[0287] To a solution of Z-Val-Osu (1.74 g, 5 mmol) in dimethoxyethane (15 ml) was added a solution of L-Citrulline (Cit, 1.31 g, 7.5 mmol) and NaHCCh (630 mg, 7.5 mmol) in DI water (10 ml) and stirred for 30 min at 0 °C. Then, the mixture was stirred vigorously for another 16 h at room temperature. Water (20 ml, containing 2 ml of saturated NaHCOs) was added, and the mixture was then washed with EtOAc (50 ml x 3) and then acidified to pH 3 with 1 N HCI. The resulting suspension was extracted with 10% n-butanol / EtOAc (50 ml x 3). The combined organic layers were dried with anhydrous Na2SO4 and concentrated in vacuo to give a white solid (3.39 g, 96% yield).
[0288] 1H NMR (400 MHz, DMSO-ds): 6 7.28-7.38 (m, 5H), 5.03 (s, 2H), 4.14 (d, J = 13.2 Hz, 5.2 Hz,1 H), 3.92 (d, J = 8.8 Hz, 7.2 Hz,1 H), 2.95 (t, J = 6.4 Hz, 1 H), 1.92-2.00 (m, 1H), 1.66-1.74 (m, 1H), 1.55-1.61 (m, 1 H), 1.35-1.41 (m, 2H), 0.88 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H).13C NMR (101 MHz, DMSO-de): 6 173.6, 173.0, 171.5, 159.0, 156.2, 137.2, 128.5, 127.9, 127.8, 65.3, 60.0, 52.00, 30.6, 28.5, 26.7, 25.3, 19.3, 18.2. (ESI+): m / z = 409.3 [M+H]+.
[0289] Synthesis of compound 16
[0290] To a solution of Z-Val-Cit (816.4 mg, 2 mmol) and N-ethoxycarbonyl-2-ethoxy-1,2- dihydroquinoline (741.9 mg, 3 mmol) in THF (10 ml) was added a solution of 4-aminobenzyl alcohol (369.5 mg, 3 mmol) in THF (5 ml) at room temperature and stirred for 8 h at 0 °C. After finishing the reaction, the solvent was removed in vacuo to obtain the residue, which was then washed with ice diethyl ether (25 ml x 3) and EtOAc (25 ml x 3) to give the pure product 16 (923.9 mg, 90% yield) as a white solid.1H NMR (400 MHz, DMSO-de): 5 8.07 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.30-7.37 (m, 5H), 7.24 (d, J= 8.4 Hz,1 H), 5.04 (s, 1H), 4.43 (s, 3H), 3.92 (t, J = 7.6 Hz, 1 H), 2.89-3.05 (m, 1 H), 1.94-2.01 (m, 1 H), 1.55-1.74 (m, 2H), 1.31-1.48 (m, 1 H), 0.88 (d, J = 6.4 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H).13C NMR (101 MHz, DMSO-de): 6 171.2, 170.4, 158.9, 156.2, 137.5, 137.5, 137.1 , 128.3, 127.8, 127.6, 126.9, 118.9, 65.4, 62.6, 60.1 , 53.0, 30.4, 29.5, 26.7, 19.2, 18.1. (ESP): m / z = 514.4 [M+H]+.
[0291] Synthesis of compound 17
[0292] To a solution of compound 16 (256.6 mg, 0.5 mmol) in THF (10 ml) was added PBr3(189.8 pl, 2.0 mmol) and stirred for 6 h at 0 °C. After finishing the reaction, the reaction was extracted with saturated NaHCOs (50 ml x 3) and EtOAc (50 ml x 3). The combined organic layers were dried with anhydrous Na2SO4 and concentrated in vacuo to give a white solid without purification.
[0293] Synthesis of compound 18
[0294] To a solution of compound 17 (0.5 mmol) and CS2CO3 (162.9 mg, 0.5 mmol) in THF / ACN (2 ml / 2 ml, V / V) was added compound 15 (185.8 mg, 0.25 mmol) and stirred for4 h at 0 °C. After monitoring the reaction by HPLC, the residue was then purified by HPLC to obtain pure product 18 (207.4 mg, 67% yield) as an orange solid.
[0295] 1H NMR (400 MHz, DMSO-ds): 5 8.50 (s, 1 H), 8.28 (d, J = 2 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.75 (d, J= 16.4 Hz, 1 H), 7.61-7.64 (m, 3H), 7.41-7.43 (m, 2H), 7.34- 7.38 (m, 6H), 6.89 (s,1 H), 5.24 (s, 2H), 5.04 (s, 2H), 4.43 (dd, J = 7.6 Hz, 7.2 Hz, 1 H), 3.92- 3.95 (m, 1 H), 3.28 (s, 1 H), 3.21 (s, 3H), 2.95-3.04 (m, 2H), 1.78-2.01 (m, 13H), 1.68-1.72 (m, 5H), 1.61 (m, 4H), 0.88 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H).13C NMR (101 MHz, DMSO-d6): 6 171.1 , 170.5, 158.0, 157.4, 156.1 , 155.1 , 148.2, 139.4, 138.6, 137.0, 136.3, 132.4, 130.9, 129.4, 128.8, 128.2, 128.1 , 127.7, 127.5, 125.8, 125.7, 125.2, 122.0, 120.7, 118.9, 117.6, 116.0, 114.8, 110.9, 88.4, 70.2, 67.7, 65.9, 65.3, 60.0, 56.4, 53.0, 50.2, 36.4, 32.1, 30.3, 29.4, 29.1 , 28.9, 28.6, 27.5, 26.7, 25.6, 24.9, 22.0, 19.1 , 18.1 , 13.9. (ESP): m / z = 1239.2 [M+H]+.
[0296] Synthesis of compounds cRGD-free MRAP and MRAP
[0297] To a solution of compound 18 (24.8 mg, 0.02 mmol) and alkyne-PEG2000-cRGD or alkyne- PEG2000-GMe (0.02 mmol) in DMSO (4 ml) was added a solution of CuSO4-5H2O (0.25 mg, 0.001 mmol) and ascorbic acid sodium (0.99 mg, 0.005 mmol) in DI water (0.4 ml) under N2atmosphere and stirred at room temperature for 4 h. After completing the reaction, the mixture was dialyzed against DI water (spectra / pore, MWCO 2.5 KDa) and then freeze-dried to give corresponding compounds. cRGD-free MRAP (64.7 mg, -100% product yield) was obtained as an orange powder.
[0298] 1H NMR (400 MHz, DMSO-de): 6 8.50 (s, 1 H), 8.27 (d, J = 2.4 Hz, 1 H), 8.10 (d, J = 3.2 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1 H), 7.75 (d, J = 16.4 Hz, 1H), 7.61-7.64 (m, 3H), 7.44-7.56 (m, 2H), 7.40 (s, 1 H), 7.33 (m, 6H), 6.89 (s, 1 H), 5.41 (s, 2H), 5.04 (s, 2H), 4.41-4.46 (m, 1 H), 4.14 (d, J = 2.0 Hz, 1 H), 4.08-4.11 (m, 2H), 3.90-3.95 (m, 2H), 3.51-3.54 (m, 176H), 3.41-3.44 (m, 4H), 3.34 (s, 3H), 3.24 (s, 3H), 3.20 (s, 1 H), 1.77-2.02 (m, 13H), 1.60-1.73 (m, 9H), 0.83-0.88 (m, 6H).
[0299] MRAP (74.4 mg, -100% product yield after click reaction and -80% cRGD grafting yield) was obtained as an orange powder.
[0300] 1H NMR (400 MHz, DMSO-d6): 6 8.50 (s, 1 H), 8.27 (d, J = 1.6 Hz, 1 H), 8.10 (d, J = 2.0 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1 H), 7.74 (d, J = 16 Hz, 1 H), 7.61-7.63 (m, 3H), 7.40-7.45 (m, 2H), 7.40 (s, 1H), 7.34-7.37 (m, 6H), 7.17-7.24 (m, 4H), 6.89 (s, 1 H), 5.42 (s, 2H), 5.03 (s, 2H), 4.51 (s, 1.6H), 4.43-4.44 (m, 1H), 4.13-4.14 (m, 4H), 3.93-3.95 (m, 1.6H), 3.88 (d, J = 1.6 Hz, 2H), 3.90-3.95 (m, 2H), 3.51-3.69 (m, 176H), 3.39-3.42 (m, 4H), 3.34 (s, 3H), 3.25-3.28 (m, 3H + 3.2H), 3.20 (s, 3H), 2.94-3.09 (m, 4H), 2.67-2.80 (m, 1.6H), 1.77-2.07 (m, 13H), 1.49- 1.71 (m, 9H + 8H), 0.83-0.88 (m, 6H).
[0301] Example 2. Optical properties of DPAs and IDPAs
[0302] The optical properties of DPAs and IDPAs were investigated in an aqueous solution (Figs. 2 and 3). After X-ray irradiation (250 pGy s"1) for 20 s, DPAs and IDPAs showed radio afterglow with emission maxima ranging from 624 to 792 nm (Fig. 4c), with the spectral profiles close to their fluorescence (Fig. 3). The presence of iodine did not change the emission maximum; however, it increased the radio afterglow intensities (~1.62-fold for IDPAo versus DPAo, 6.46- fold for IDPAsu versus DPAsu, 6.65-fold for IDPAse versus DPAse) (Fig. 4d). Their half-lives ranged from 9.2 to 196.8 min (Fig. 4e). Among them, IDPAsu had the highest brightness and relatively longer emission maximum at -773 nm, with a long-lasting radio afterglow up to -25 h (Fig. 5). Meanwhile, the radio afterglow of IDPASu could be repetitively induced with minimal intensity decrease after ten cycles (Fig. 4f) as one cycle of irradiation consumed only -3% of IDPAsu (Fig. 6), showing its ability for longitudinal imaging.
[0303] Example 3. Radio afterglow mechanism of organic luminophores
[0304] To study the radio afterglow mechanism, the sample of IDPASuafter X-ray irradiation was analysed with HPLC and high-resolution mass spectrometry.
[0305] ESR study of ROS generation
[0306] To study1C>2 generation, a mixture of DPAS or IDPAS (100 pM) and TEMP (10 mM) in PBS (0.01 M, pH 7.4, 50% DMSO) was irradiated by X-rays at 2 Gy (100 mGy s"1for 20 s) or 5 mGy (250 pGy s-1for 20 s). The ESR signals of the mixture were recorded with a Bruker A300 instrument. The ESR signal of the free radical 2,2,6,6-tetramethyl-1-piperidinyloxyl (g = 2.0060) was generated by the reaction of1O2 with TEMP. The1O2 quencher NaNs (1 mM) was added to validate the afterglow mechanism of IDPAsu. Additionally, other commercially available radio sensitizers (such as acridine orange, hematoporphyrin and verteporfin) were measured and compared. The procedure of block depths was similar to that of the tissue penetration depth study and the1O2 generation for different depth tissues was measured. The ESR signal changes of MRAP in the absence or presence of CatB were measured in a similar way. The ESR signals of 2,2,6,6-tetramethyl-1-piperidinyloxyl from the reaction of1©2 with TEMP were plotted as a function of the concentration of1O2, which was generated by the addition of NaOCI to H2O2. This generated the standard curve between the ESR intensity and1C>2 concentration. To study other ROS generation, fluorescence sensors DHR123 (for O2'“ detection) and HPF (for "OH detection) were used. For O2" detection, DHR123 (10 pM) was added to a solution of IDPAsu (10 |JM) in PBS (0.01 M pH 7.4, 50% DMSO), followed by X-ray irradiation at different doses of 5 mGy (250 pGy s"1for 20 s) and 2 Gy (100 mGy s"1for 20 s). The fluorescence changes in DHR123 were recorded at 4exof 505 nm and 4emof 534 nm. For OH detection, HPF (10 pM) was added in a solution of IDPASu (10 pM) in PBS (0.01 M, pH 7.4, 50% DMF), followed by X-ray irradiation at different doses, namely, 5 mGy (250 pGy s"1for 20 s) and 2 Gy (100 mGy s"1for 20 s). The fluorescence changes in HPF were collected at JXof 450 nm and 4emof 515 nm. The ROS production was calculated by the corresponding standard curve.
[0307] Results and discussion
[0308] The HPLC profile of X-ray-irradiated IDPAsu (AIDPASu) (Fig. 4g) showed two new elution peaks at 6.0 and 14.8 min with a conversion yield of 7.6% and 3.3%, respectively. The high-resolution mass spectrometry analysis revealed that the products peaking at 6.0 and 14.8 min had a mass of 510.9619 and 661.0652, which were assigned to activated IDPASuand a dioxetane compound, respectively (Figs. 7b-c).
[0309] To explore the influence of iodine atom on radio afterglow and radiodynamic activity, the DIDPAx (X = O and S) with two iodine substituent groups were first synthesized. The radio afterglow intensities of DIDPAo and DIDPAs were extremely low even after increasing X-ray dosage as two iodine atoms made very low quantum yield (Figs. 8a-c). However, the radiodynamic activities showed a slightly increase (Figs. 8d-f). For example, X-ray triggered1O2 generation from DIDPAs displayed ~1 .2-fold higher than that of IDPAS.
[0310] The formation of the dioxetane intermediate indicates that ROS were generated from X-ray irradiation. This was confirmed by ESR spectroscopy, showing the generation of1O2 by DPAsu and IDPAsu under X-ray irradiation (Fig. 4h). Among them, the generation of1O2 by IDPAsu was the highest (Figs. 4i and 9); moreover, other ROS were undetectable and only minimal O2'- could be generated at elevated radiation dosage (Fig. 10).
[0311] Table 1. The linear regression equation in Fig. 9.
[0312] These data reveal that the radio afterglow mechanism of DPAs and IDPAs is closely associated with the radiodynamic process (Fig. 4b). First, the X-ray irradiation of DPA or I DPA leads to the radiodynamic generation of1C>2. Then, the in situ-generated1C>2 reacts with DPA or I DPA via a cycloaddition reaction and converts it into a dioxetane intermediate. At last, this intermediate gradually decomposes into the corresponding activated products (activated DPA or IDPA) and releases photons. Although both luminophores generated1C>2 under X-ray irradiation, the presence of heavy iodine in IDPAs can not only enhance their X-ray absorption but also efficiently populate triplet excitons. Thus, IDPAs radiodynamically produced more1O2 than the iodine-free counterparts, which facilitated the formation of the dioxetane intermediate and consequently emitted stronger radio afterglow. Note that the radiodynamic1C>2 generation of IDPAsu was at least 5.7 times higher than the commercially available radio sensitizers including acridine orange (AO), hematoporphyrin (HP) and verteporfin (VP), showing its high promise for RDT.
[0313] Example 4. Deep-tissue radio afterglow dynamic performance
[0314] The tissue penetration of radio afterglow by IDPAsu was compared with photoafterglow.
[0315] Screening for radio afterglow molecules
[0316] DPAs or IDPAs (100 pM) in 0.01 M PBS (pH 7.4, 50% DMSO) were irradiated by X-rays at 250 pGy s-1for 20 s (total, 5 mGy) under the specific setup parameter of 10 kV and 75 pA. Then, the radio afterglow signal was collected with an IVIS imaging system under the bioluminescence mode with an open filter and an acquisition time of 60 s. Finally, the radio afterglow intensities were quantified by a region-of-interest analysis using Living Image 4.3 software. In addition, the radio afterglow spectra of the candidates were acquired under the same test conditions with specific emission filters, and time courses of the signal were recorded as a function of time.
[0317] Tissue penetration depth study IDPAsu (100 pM, 100 pl) solution in a round cap with a diameter of 1 cm was prepared and placed under the chicken breast tissue with different thicknesses (0, 1.0, 2.5, 5.0, 10.0 and 15.0 cm). To avoid the influence of afterglow intensity differences on tissue penetration, the X-ray source (Moxtek, Inc.) and xenon lamp (PLS-SEX300D, Beijing Perfectlight Technology Co., Ltd.) were optimized to ensure that all the samples at 0 cm (without coverage) received the same dose of X-rays (5 mGy, 250 pGy s-1for 20 s) or light (180 mW cm-2for 20 s) and thus the same afterglow intensity. After the cessation of irradiation, radio afterglow or photoafterglow was detected with or without the chicken breast tissues using the MS bioluminescence mode with an open filter and acquisition time of 120 s.
[0318] Measurement of limit of detection (LOD)
[0319] To test the LOD of IDPAsu for in vivo RAI, 20 pl of the mixture solution of IDPAsu at different concentrations (100.0, 50.0, 20.0, 10.0, 5.0, 1.0, 0.5 and 0 pM) and solubilizing agent (2- carboxyethyl)-p-cyclodextrin sodium salt (|3-CD) at 100 pM was subcutaneously injected into the left flank of BALB / c nude mice (six weeks old). After 30 min, the left flank of mice were irradiated with X-rays at 5 mGy (250 pGy s"1for 20 s) as the other areas were protected by a 3.4-mm-thick lead shield with a notch under the X-ray irradiation. Radio afterglow signals were recorded. The detection limit was calculated using this equation: LOD = 3a / k, where cr represents the s.d. of blank and k implies the slope of the radio afterglow intensities.
[0320] To study the LOD of MRAP for CatB detection, MRAP (100 pM) was incubated in PBS (0.01 M, pH 7.4), EDTA (1 mM) and glutathione (5 mM) with different concentrations of CatB (0, 0.10, 0.25, 0.50, 1.00 and 5.00 pg ml'1) for 6 h, followed by X-ray irradiation (5 mGy, 250 pGy s"1for 20 s). After irradiation, the signals were immediately recorded. The LOD was determined as LOD = 3ulk.
[0321] Confocal microscopy
[0322] Confocal microscopy images were acquired on a Nikon A1 confocal laser scanning microscope (Nikon Instruments). The tissue sections were examined using Leica RM2016 (Leica Inc.) and an ECLIPSE 80i microscope (Nikon Instruments).
[0323] Histological analysis
[0324] For H&E staining, tumours and organs were fixed with 4% paraformaldehyde, dehydrated in the graded ethanol solution (100%, 90% and 75%), embedded in paraffin and cut into sections with a thickness of 5 pm. The sections were incubated with haematoxylin for ~3-5 min and eosin for 5 min, followed by washing with distilled water. Then, the sections were hydrated and sealed for observation under microscopes. For immunofluorescence staining, the tumours were fixed with 4% paraformaldehyde, dehydrated using 30% sucrose aqueous solution, followed by embedding in frozen optimal cutting temperature medium. Then, the entire tissue block was frozen by liquid nitrogen and was transferred to a cryotome cryostat (-20 °C, Leica Biosystems). The block was cut into the desired section with a thickness of 10 pm and the sections were placed on glass slides, followed by drying at 25 °C for 60 min. The sections were washed thrice with 0.1 % Triton X-100 in PBS (0.01 M, pH 7.4) and incubated with 3.0% bovine serum albumin for 1 h at 25 °C. Then, the sections were washed with PBS (0.01 M, pH 7.4) and incubated with the corresponding antibodies (anti-cleaved caspase-3 antibody and anti-caspase- 1 antibody) for 1 h, followed by washing thrice with PBS. The sections were counterstained with Alexa Fluor 594 secondary antibody for 1 h at 25 °C. DAPI was used to stain the cell nuclei, and the sections were observed by a confocal laser scanning microscope. TUNEL or anti-cleaved caspase-3 staining was conducted according to the protocol (Abeam company). For SOSG staining, subcutaneous U87-tumour-bearing mice were intratumorally injected with PBS (20 pl) and IDPASu(0.1 pmol kg-1, solubilized with 0.1 pmol kg-1of p-CD). After 30 min post-injection, the tumour was locally injected with an SOSG sensor (20 pl, 100 pM) and subsequently treated with or without X-ray irradiation (0.1 Gy, 5 mGy s"1for 20 s). After that, the mice were euthanized to collect the tumour, which was fixed with 4% paraformaldehyde, and cut into sections (10 pm). These tumour sections were also stained with DAPI and then observed using the confocal laser scanning microscope. The fluorescence intensity of SOSG in each picture was quantified by Imaged v1.51a software. The procedure for SOSG staining in the orthotopic U87 tumour model was similar to that in the subcutaneous U87 tumour model.
[0325] Heat generation study
[0326] IDPAsu (100 pM, 100 pL) solution and PBS in a round cap with the diameter of 1 cm were prepared and then irradiated by X-ray at dose of 5 mGy (250 pGys1for 20 s), respectively. The temperatures of the IDPAsu solution and PBS were recorded by FLIR Infrared Camera (FLIR A35-Series, FLIR Systems).
[0327] Results and discussion
[0328] To induce afterglow, IDPAsu was irradiated with X-ray or light through chicken breast tissues before signal detection (Figs. 11a-b). To eliminate the influence of intensity difference on tissue penetration, X-ray and light irradiation were optimized to ensure similar intensity without tissue coverage. At the tissue depth of 1 cm, photoafterglow was hard to induce due to light scattering and reflection, showing the intensity (7.20 x 104photons s1cm2sr1) slightly higher than the background (-6.10 x 103photons s1cm2sr1); in contrast, radio afterglow reached -1.79 x 10sphotons s1cm2sr1(Fig. 11e). Radio afterglow of IDPAsu was inducible and detectable even through -15 cm tissue, showing ~4.2-fold higher signal than that of IDPAsu without X-ray irradiation and tissue (Fig. 11d).
[0329] The deep-tissue radiodynamic process of IDPAsu was tested by measuring1C>2 generation at different tissue depths and compared with photosensitization (Fig. 11c). Without tissue coverage, both X-ray and light effectively induced1C>2 generation from IDPAsu. At the tissue depth of 1 cm, the concentration of1C>2 generated by the X-ray irradiation of IDPASuslightly decreased by -30%; in contrast, it was close to the background for light irradiation. Furthermore, the radiodynamic generation of1C>2 for IDPASuwas still inducible at a tissue depth of 15 cm.
[0330] To validate the suitability of IDPAsu for cancer radio theranostics, the cell viabilities with and without X-ray irradiation were studied (Fig. 12). IDPAsu itself exhibited 91 % viability even at a high concentration of 100 pM. However, under X-ray irradiation (2 Gy, 100 mGy s-1for 20 s), the viability drastically dropped to 1.4% due to the production of cytotoxic1C>2. Such a radio therapeutic effect was still inducible even at the tissue depth of 15 cm (31.9%). The radio afterglow signals of the IDPAsu solution had a linear correlation with its concentrations, and radiation did not cause any heat generation even at a concentration of 100 pM of IDPAsu (Fig. 7e). The in vivo imaging sensitivity of IDPAsu was studied by detecting the radio afterglow of subcutaneously injected IDPAsu, showing a LOD of IDPAsu as low as 49 nM (Fig. 13). The RDT ability was validated by the intratumoral injection of IDPAsu into the tumour-bearing nude mice followed by X-ray irradiation with a total dosage of 0.3 Gy in three fractions (see Example 6 for more details). This IDPAsu-mediated RDT completely inhibited the tumour growth and caused no loss in body weight (Fig. 14). These data confirm that IDPAsu is promising for cancer theranostics.
[0331] Table 2. The linear regression equation in Fig. 13b.
[0332] Example 5. Molecular radio afterglow dynamic probe (MRAP)
[0333] CatB selectivity
[0334] MRAP (100 M) was incubated with different enzymes including ALP (5 U ml1), |3-gal (5 U ml1), furin (5 U ml1), NTR (5 pg ml1), GGT (5 pg ml1), CatB (5 pg ml1), APN (5 U ml1) and uPA (5 U ml1) for 6 h in their optimized buffer conditions according to the corresponding protocol from R&D Systems.
[0335] Cell RAI
[0336] To study the cellular RAI, MRAP (100 pM) was added to different cell counts (1 , 2, and 4 x 104) of U87 or 3T3 medium for 12 h incubation, followed by X-ray irradiation (5 mGy, 250 pGy s’1for 20 s). The inhibitor group was pretreated with a CatB inhibitor (CA-074, 1 mM) for 10 h. The radio afterglow signals from each well were recorded with an MS imaging system with an open filter (120 s acquisition time).
[0337] Results and discussion
[0338] To enable precision cancer diagnosis and therapy, IDPAsu was modified into a MRAP (as described in Example 1) that only activated its radio afterglow and radiodynamic functions in the presence of a tumour biomarker, namely, cathepsin B (CatB) (Figs. 15a and 16). CatB was chosen because it is upregulated in multiple cancer cells, playing a role in tumour growth and progression. MRAP comprises three key units: a tumour-targeting moiety (cRGD), a radio afterglow dynamic theranostic moiety and a CatB-cleavable peptide moiety (Cit-Val). In the absence of CatB, MRAP had negligible radio afterglow and radiodynamic1O2 generation (Figs. 15b, d), because the electron-donating ability of the oxygen atom of the phenol unit in the phenoxy-adamantylidene unit was diminished, inhibiting its intramolecular charge transfer. In the presence of CatB, the peptide moiety was cleaved to liberate uncaged MRAP as confirmed by HPLC (Fig. 17c), leading to the activated radio afterglow at -770 nm with 312-fold signal enhancement (Figs. 15b and 17d). MRAP showed a superior selectivity towards CatB over other enzymes such as alkaline phosphatase (ALP), aminopeptidase N (APN), furin, gammaglutamyl transferase (GGT), nitroreductase (NTR), p-galactosidase (p-gal) and urokinase plasminogen activator (uPA) (Fig. 15b). Moreover, the radio afterglow intensity of MRAP had good linearity with the concentration of CatB, with a low LOD of -1.22 ng ml1(Fig. 17e). The biomarker-activatable radiodynamic effect of MRAP was validated by ESR, showing the ESR signal of1C>2 increase by 7.8-fold on the incubation of MRAP with CatB followed by X-ray irradiation (Figs. 15d and 17f).
[0339] After confirming its good cytocompatibility (Fig. 18a), the biomarker specificity of MRAP was tested in U87 glioblastoma cells (CatB positive) and 3T3 fibroblast cells (CatB negative) (Fig. 15e). After incubation with MRAP and radiation, strong radio afterglow was observed for U87 cells (Fig. 15f), which was in sharp contrast to the signal for 3T3 cells and U87 cells pretreated with CA-074 (a CatB inhibitor), showing the signal as low as the background. At the cell counts of 4 x 104per well, the radio afterglow intensity of U87 cells was 78.5-fold higher than that of the 3T3 cells. Following X-ray irradiation, the cell viability of CatB-overexpressed cells decreased with increasing MRAP concentration, whereas no obvious toxicity was observed for cells with low CatB expression even at a high concentration of MRAP (100 pM) (Fig. 15g). For example, the cell viability of U87 cells decreased with the increased MRAP concentration, reaching 38.2% at 10 pM; in contrast, the cell viability of MRAP-treated 3T3 cells remained close to 100% regardless of the MRAP concentration. Thus, MRAP was only activated in U87 cells, verifying that its radio afterglow and radiodynamic toxicity was specific to CatB. This molecular radio afterglow dynamic selectivity of MRAP was also observed for solutions (Fig. 17f) and cells (Figs. 18b-d) covered with a 15-cm-thick tissue, showing its potential for precision deep-tissue cancer theranostics.
[0340] Example 6. In vivo cancer radio afterglow dynamic theranostics
[0341] Pharmacokinetics studies
[0342] Healthy BALB / c nude mice (six weeks old, female) were intraperitoneally injected with ketamine (50 mg kg-1) for anaesthesia. Each group has three mice. At different timepoints (0.6, 1.2, 6.0, 30.0, 60.0, 120.0, 240.0, 480.0, 720.0 and 1 ,440.0 min) after an intravenous injection with MRAP or cRGD-free MRAP (10 pmol kg-1), blood was collected from the eye socket vein and stored in heparin tubes in an ice bath. The plasma was obtained by blood sample centrifugation at 1 ,200 x g for 20 min. The blood concentrations of MRAP and cRGD- free MRAP were determined by HPLC analysis, and their plasma half-life (fi / z) was calculated.
[0343] Blood analyses were conducted with an automatic biochemical analyser (Chemray 240).
[0344] Tumour implantation
[0345] To establish a subcutaneous glioblastoma mouse model, BALB / c nude mice (six weeks old, female) were anaesthetized with isoflurane (2.0%) and subcutaneously injected with human U87 or U87-Luc (2 x 10® per mouse) suspended in PBS (0.01 M, pH 7.4) on the left flank or bilateral flank of each mouse. The tumour size was calculated according to the formula V = M2ab2, where a and b are the longest and shortest diameter of the tumour, respectively. After tumour sizes reached ~70 mm3, the mice were used for imaging and therapy. To establish the orthotopic glioblastoma mouse model, BALB / c nude mice (six weeks old, female) were anaesthetized with isoflurane (2.0%) and fixed in a stereotactic instrument (RWD Life Science, E03143) for a skin incision on the brain region of interest: +0.5 mm anterior- posterior, +0.2 mm medial-lateral, -2.8 mm dorsal-ventral relative to the bregma. Then, human U87-Luc cells (2 x 105per mouse) suspended in PBS (0.01 M, pH 7.4) were implanted through a burr hole with a size of 1 mm2by a microsyringe. The injection process lasted for 15 min. The burr hole was sealed by bone wax, and the skin incision was closed with surgical clips. To monitor the tumour growth, mice were intraperitoneally injected with d-luciferin sodium salt (500 pmol kg"1). At 15 min post-injection, bioluminescence signals were recorded using an I VIS imaging system with an open filter and automatic acquisition time. Mice were used for imaging and therapy after the bioluminescent signal of orthotopic tumours reached up to -1-2 x 1O6photons s1cm2sr1.
[0346] Biodistribution studies
[0347] Orthotopic U87-tumour-bearing mice were intravenously injected with MRAP or cRGD-free MRAP (10 pmol kg"1). At 24 h post-injection, the mice were sacrificed and major organs and tumours were collected for homogenization in PBS (0.01 M, pH 7.4). The homogenates were centrifuged at 1 ,585 x g for 20 min to remove the insoluble components. The supernatants containing MRAP or cRGD-free MRAP were analysed by HPLC. MRAP or cRGD-free MRAP concentration in tissues was calculated by the calibration curves obtained from its solutions of known concentrations, and converted into percent of injected dose per gram of tissue (%ID g-1).
[0348] RDI studies
[0349] For in vivo RAI by IDPAsu, subcutaneous U87-tumour-bearing mice were intratumorally injected with IDPAsu (100 pM, 20 pl) solubilized with p-cyclodextrin (100 pM). Each group has three mice. At different post-injection timepoints (0, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 16.0 and 24.0 h), the tumours were irradiated with X-rays (5 mGy, 250 pGy s"1for 20 s), followed by radio afterglow detection using the I VIS imaging system under the bioluminescence mode with an open filter and acquisition time of 120 s. Tumour-free areas were protected by a 3.4-mm- thick lead shield with a notch. For in vivo RAI by MRAP, MRAP or cRGD-free MRAP (10 pmol kg"1) were intravenously injected into orthotopic U87-tumour-bearing mice. At different postinjection times (0, 2, 6, 12, 24, 36 and 72 h), mouse brains were exposed to X-ray irradiation and the other areas were protected by a 3.4-mm-thick lead shield with a notch. Radio afterglow signals from brain tumours were recorded with the IVIS imaging system under the bioluminescence mode with an open filter and acquisition time of 120 s. For ultrasmall-tumour detection, U87-Luc cells (2 x 1 osper mouse) were subcutaneously implanted into the left flank of each mouse. The tumour sizes were calculated as per the above-mentioned equation, showing ~0 mm3for 1 day post-implantation, 6 mm3(tumour diameter, 2.3 mm) for 5 days post-implantation, 22 mm3for 10 days post-implantation, 43 mm3for 20 days post-implantation and 77 mm3for 30 days post-implantation. At 15 min post-intraperitoneal injection of aqueous d-luciferin sodium salt (500 pmol kg-1) solution into mice with different tumour sizes, the bioluminescence signals from the tumour sites were recorded with the IVIS imaging system under the bioluminescence mode with an open filter and automatic acquisition time. At 4 h post-intraperitoneal injection of d-luciferin sodium salt, no bioluminescence signal was observed, followed by an intravenous injection of MRAP (10 pmol kg-1) in U87-Luc-tumour- bearing mice. At 20 h post-injection of MRAP, radio afterglow signals from tumour sites after X-ray irradiation (5 mGy, 250 pGy s-1for 20 s) were recorded by the IVIS imaging system under the bioluminescence mode with an open filter and acquisition time of 120 s.
[0350] RDT studies
[0351] For subcutaneous tumour therapy, to study the X-ray dynamic activity of IDPASu, U87-tumour- bearing mice were randomly divided into four groups (PBS, PBS + X-ray, IDPASuand IDPASu+ X-ray), which includes five mice per group. On day 0, tumours were intratumorally injected with PBS or IDPAsu (0.1 pmol kg-1, solubilized with 0.1 pmol kg-1of p-CD) and irradiated with X-rays (0.1 Gy, 5 mGy s-1for 20 s) at 30 min post-injection. During the therapy, the mice were anaesthetized by intraperitoneally injected ketamine (50 mg kg-1) in saline. Such therapy was performed every three days. Only the tumour site was irradiated by X-rays as the other areas were protected by a 3.4-mm-thick lead shield with a notch. The tumour volume and body weight of mice were monitored every two days. The tumours and main organs were collected for histological analysis after therapy (H&E and TUNEL staining). For orthotopic glioblastoma therapy, orthotopic U87-tumour-bearing mice were randomly divided into four groups (PBS, PBS + X-ray, MRAP and MRAP + X-ray; n = 5 mice per group). On day 0, mice were intraperitoneally injected with d-luciferin sodium salt and PBS (0.01 M, 200 pl) for bioluminescence imaging. After 4 h when no bioluminescence signal of luciferin on the brain was observed, the mice were intravenously injected with or without MRAP (10 pmol kg-1) and not irradiated or irradiated with X-rays (0.8 Gy, 40 mGy s~1for 20 s) at 24 h post-injection. The whole brain was irradiated by X-rays with a binning area of 6.03 cm2as the other areas were protected by a 3.4-mm-thick lead shield with a notch during X-ray therapy. To avoid lethal brain oedema, dexamethasone (5 mg kg-1) was intramuscularly injected at the right hind limb of each mouse at 18 h before and 6 h after X-ray irradiation. During the therapy, mice were anaesthetized by intraperitoneally injected ketamine (50 mg kg-1) in saline. The brain tumour size was monitored using bioluminescence signals of luciferin from the tumour site every three days. Mice were euthanized when they either lost 20% of their body weight or presented any obvious signs and symptoms of sickness during the therapy. Tumours and main organs were collected for histological analysis after therapy (H&E and caspase-1 staining). For precision and biocompatibility studies, MRAP (0.5 pmol kg-1) was intracranially injected into the brain of orthotopic U87-tumour-bearing mice through a burr hole with a size of 1 mm2by a microsyringe. For comparison, uncaged MRAP (0.5 pmol kg"1) was intracranially injected into the brain of healthy mice. At 30 min post-injection of MRAP or uncaged MRAP, both in vivo and ex vivo radio afterglow signals from the brain after X-ray irradiation (2 Gy, 100 mGy s-1for 20 s) were recorded by the I VIS imaging system under the bioluminescence mode with an open filter and acquisition time of 120 s. Only brains were exposed to X-ray irradiation and the other body areas were protected by a 3.4-mm-thick lead shield with a notch. Furthermore, the brains were fixed and sectioned for histological analysis (H&E and anti-cleaved caspase-3 staining).
[0352] Results and discussion
[0353] The ability of MRAP for cancer radio afterglow dynamic theranostics was validated in intracranial glioblastoma mouse model using luciferase-expressed U87 cancer cell line (U87- Luc). After 14 days of U87-Luc tumour implantation, longitudinal RAI was conducted via the intravenous injection of MRAP or cRGD-free MRAP into the U87-tumour-bearing mice (Fig. 19a). The radio afterglow signals for both MRAP and cRGD-free MRAP gradually increased and reached the maximum at 24 h post-injection (Figs. 19b-c), showing the tumour- to-background ratios (TBRs) of -173 and 38, respectively. In contrast, the signal remained as low as the background for tumour-free healthy mice. The higher TBR of MRAP relative to cRGD-free MRAP was attributed to the targeting capability of cRGD towards av[33 integrin overexpressed in the tumour, which was also verified by the higher percent injected dose (I D%) of MRAP (10.4%) relative to cRGD-free MRAP (3.1%) at 24 h post-injection (Fig. 20a). Then, the pharmacokinetics of both probes and fragments were studied (Figs. 20b-c). The plasma elimination half-life (fi / 2) of MRAP was -4.2 h, slightly longer than that of cRGD-free MRAP (fi / 2= -3.1 h).
[0354] After confirming the highest signal 24 h post-intravenous injection of MRAP, MRAP-mediated RDI was scheduled on day 0, 3, 6 and 9 with a fraction dosage of 0.8 Gy (Fig. 19a). The tumour growth was continuously monitored by a bioluminescence signal from U87-Luc cells in mice intraperitoneally injected with d-luciferin (Fig. 21). After RDT for four times, the tumour growth was completely inhibited, whereas other groups showed no obvious regression or inhibition of the tumour growth (Fig. 19d). Therefore, the survival time for MRAP-mediated RDT groups were increased from 37 days (phosphate- buffered saline (PBS)) to 76 days, showing a 100% survival rate until 67 days (Fig. 19e). As verified by H&E staining on day 21 , the tumour tissue was only -1.61 mm2after MRAP-mediated RDT, which was -5.74 times smaller than the PBS + X-ray group (-9.24 mm2) (Fig. 19f) . Moreover, the density of cancer cells in the tumour tissue for MRAP-mediated RDT was much lower than the other groups (Figs. 19g and 22a), showing obvious cell death. SOSG immunofluorescence staining confirmed the effective in situ generation of1C»2 by MRAP in the tumour under X-ray irradiation (Fig. 19g). Similarly, caspase-1 staining and TUNEL assay revealed strong signals from the MRAP-mediated RDT group, suggesting the pyroptosis and apoptosis of cancer cells. Note that no obvious loss in body weight and sign of tissue damage was detected in major organs of mice after MRAP-mediated RDT (Figs. 22b-c).
[0355] Example 7. Sensitivity and precision studies
[0356] The sensitivity of MRAP for cancer detection was tested in a subcutaneous U87-Luc-tumour- bearing mouse model. MRAP was intravenously injected into mice bearing U87-Luc tumours with different sizes, whereas the bioluminescence substrate (d-luciferin) was intraperitoneally injected for comparison by following the protocols in Example 6 (Figs. 23a-b). In accordance with bioluminescence imaging, RAI had a linear signal correlation with the tumour size but slightly higher intensities than bioluminescence (Fig. 23c). The LOD for tumour detection was determined to be 1.08 mm3(diameter, 0.64 mm), which was within the detection range for micrometastatic tumours (< 2.00 mm).
[0357] The precision of MRAP-mediated RDT was evaluated and compared with an ‘always-on’ control probe (Fig. 23e, uncaged MRAP). After confirming the ideal blood compatibility for both MRAP and cRGD-free MRAP at a high total dosage (100 pmol kg-1) by a routine blood analysis by following the protocol in Example 6 (Fig. 24), the probe was intracranially injected into mice with or without intracranial glioblastoma. Due to the CatB selectivity, MRAP was only activated to emit a strong signal in the tumour, whereas its signal remained low for a tumour- free healthy mouse (Fig. 23d); in contrast, the signal was always-on for the control probe in the healthy mouse. This was consistent with ex vivo brain imaging (Figs. 23d, f). After X-ray irradiation, the mice were immediately sacrificed for tissue analysis. Due to the tumour specificity, the radiodynamic function of MRAP remained inactive in the brain of healthy mouse, which was not possible for the control probe. Thus, MRAP only resulted in tissue damage and apoptotic caspase-3 signal in the tumour area of the glioblastoma mouse (Fig. 23g); in contrast, the ‘always-on’ radiodynamic function of the control probe triggered the non-specific cellular apoptosis in the brain of healthy mice. These data confirmed the high sensitivity and precision of MRAP in cancer therapy.
[0358] The utilization of X-rays to induce the photophysical processes of optical agents in deep tissues led to the emergence of RAI and RDT. These hybrid modalities not only tackle the tissue penetration issue of optical imaging and cancer phototherapy but also minimize the radiation damage to normal tissues. However, only inorganic nanophosphors are available for both applications, and their radio afterglow dynamic function is always on, limiting their specificity and efficacy in cancer detection and treatment.
[0359] T o enable radio afterglow for organic molecules, we proposed a radiodynamic approach based on organic luminophores (DPAs and IDPAs) that were able to harvest X-ray energy for an in situ cycloaddition reaction to form self-luminescent chemical defects (Fig. 4b). This is mechanistically different from inorganic nanophosphors wherein the host materials (for example, fluoride and aluminosilicate) absorb X-rays, lattice defects delay excitons, and rare- earth / transition metal ion dopants (for example, Nd3+and Eu3+) emit light (Richard, C. & Viana, B., Light.: Sci. Appl. 2022, 11, 123). Because of the presence of heavy atoms (iodine), IDPAs had higher radiodynamic1C>2 generation and stronger radio afterglow emission than the iodine- free counterpart (DPAs). The radio afterglow dynamic processes of IDPAs were inducible even at a tissue depth of 15 cm, which was impossible when using light. Moreover, IDPAs had the afterglow half-life (18.4 min) comparable with inorganic nanophosphors, but 25.4 times higher in vivo intensity based on the same mass (1.27 x 106versus 5.00 x 104photons s_1cm'2sr1pg1) (Table 3); such a higher brightness resulted in the induction and detection of radio afterglow signal in the tissue depth 2.5 times deeper than inorganic nanophosphors (5.0 versus 2.0 cm) (Fig. 24).
[0360] Table 3. Summary of X-ray-induced NIR afterglow for in vivo imaging.
[0361]
[0362]
[0363]
[0364] Note: SBR: signal-to-background ratio; N.A: not available; Ref.: reference.
[0365] To achieve high cancer theranostic specificity, a candidate radio-luminophore (IDPAsu) was developed into a smart probe (MRAP), which only turned on its radio afterglow dynamic function in the presence of a cancer biomarker (CatB). Such a biomarker-activated radio afterglow of MRAP led to the ultrahigh sensitivity, showing a TBR value that was ~5.7 times higher even than a second near-infrared radiodynamic nanophosphor (NaYF4:Er@NaYF4) for the imaging of a subcutaneous tumour (234 versus 41) (Pei, P. etal., Nat. Nanotechnol. 2021 , 16, 1011-1018). Therefore, MRAP-based RAI detected the ultrasmall tumour (6 mm3, 2.3 mm in diameter), more sensitive than clinical imaging methods (>7.0 mm) and circulating-tumour DNA sensors (>10.0 mm) (Pashayan, N. & Pharoah, P. D. P., Science 2020, 368, 589-590).
[0366] As exemplified by the comparison between MRAP and the always-on probe (Fig. 23d), the biomarker activation of MRAP ensured that the radiodynamic toxicity specifically occurred in the tumour tissue and spared the adjacent normal tissues despite the co-existence of MRAP. This is intrinsically superior over existing agents whose radio therapeutic effect is mainly dictated by their distribution and local concentration in tissues. In conjugation with the higher radiodynamic efficiency (>5.7 times higher than the commercially available radio sensitizers; Fig. 4i), IDPASu and MRAP-mediated RDT completely inhibited the tumour growth in subcutaneous and orthotopic glioblastoma mouse models at the respective total dosages of 0.3 Gy (0.038 mg) and 3.2 Gy (2.960 mg), which were much lower than other reported RDT agents, namely, >0.5 Gy (0.125 mg) and >20.0 Gy (>8.000 mg), respectively (Table 4).
[0367] Table 4. Summary of X-ray-induced NIR afterglow for in vivo imaging.
[0368]
[0369]
[0370]
[0371]
[0372]
[0373]
[0374] Note: I.V.: intravenous injection; LT.: intratumoral injection; I.P.: Intraperitoneal injection, N.A: not available; Ref.: reference.
[0375] Here we report the development of organic luminophores that can efficiently undergo a radiodynamic process to generate singlet oxygen O2) and emit radio afterglow for precision cancer theranostics. In addition to their tunable near-infrared emission, long half-life and efficient1C>2 generation, the structure versatility of these radio-luminophores enables the construction of a smart activatable probe that only switches on its radio afterglow dynamic processes in the presence of the targeted cancer biomarker. In the above examples, we have described the synthesis and properties of these radio-luminophores, study the underlying mechanisms and potential advantages over light-induced processes as well as evaluate their potential in precision diagnosis and therapy for deep-seated brain tumours in preclinical settings.
[0376] In summary, we have developed a type of organic radioluminophore that outperforms inorganic nanophosphors to emit brighter, near-infrared radio afterglow and autonomously produce radiodynamic1O2 without additives. The modular structure of these radio- luminophores facilitated the precise control of their physiological properties and construction of a smart molecular probe (MRAP) with unprecedented biomarker-activated radio afterglow dynamic function. Such a biomarker specificity of MRAP allowed the detection of a diminutive tumour with superb contrast and perform radiotherapy for deep-seated tumour with molecular precision at a low dosage. In addition, the modification of radioactive organic luminophores can potentially allow for image-guided surgery and monitoring cell therapy. Thus, our work not only reveals molecular guidelines to fill in the gap of organic radio afterglow agents but also highlights a new translational direction towards precision theranostics.
Claims
Claims1. A compound of formula la or lb:where the wiggly line represents the point of attachment to the rest of the molecule;X represents NMe, NEt, CMe2, SIMe2, O, S or Se; each R4 is independently selected from:; or an aromatic or heteroaromatic group that is unsubstituted or substituted by CO2H or OH, where: the wiggly line represents the point of attachment to the rest of the molecule;PEG is PEG1 K, PEG2K, or PEG5K; n is 0 to 11 ;LINKER represents:where n is 0 to 11 and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the TARGET GROUP;TARGET GROUP represents:where the wiggly line represents the point of attachment to the rest of the molecule; each Rs independently represents H or halo;each Ri represents H, Br or I; each R2 represents H, Cl, Br, or I;Rs either represents:the wavy line represents the point of attachment to the rest of the molecule; or R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is:where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptide is selected from:where the wavy line represents the point of attachment to the rest of the molecule, or a pharmaceutically acceptable salt or solvate thereof.
2. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Claim 1, wherein the compound has formula la.
3. The compound, or pharmaceutically acceptable salt or solvate thereof, according toClaim 1 or Claim 2, wherein R represents:where the wiggly line represents the point of attachment to the rest of the molecule; and X represents NEt, O, S or Se, such as O, S or Se, such as S.
4. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Claim 3, wherein R represents:where the wiggly line represents the point of attachment to the rest of the molecule; and X represents O, S or Se, such as S.
5. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein R4 is independently selected from:where: the wiggly line represents the point of attachment to the rest of the molecule;PEG is PEG1 K, PEG2K, or PEG5K; and n is 0 to 11.
6. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Claim 5, wherein R4 is independently selected from:where: the wiggly line represents the point of attachment to the rest of the molecule;PEG is PEG1 K, PEG2K, or PEG5K; andn is 3 to 5, such as 4.
7. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein, when present, LINKER represents:, where n is 3 to 5, such as 4, and the wiggly line represents the point of attachment to the oxygen atom and the dotted line represents the point of attachment to the TARGET GROUP.
8. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein, when present, TARGET GROUP represents:where the wiggly line represents the point of attachment to the rest of the molecule.
9. The compound, or pharmaceutically acceptable salt or solvate thereof, according to Claim 8, wherein, when present, TARGET GROUP represents:where the wiggly line represents the point of attachment to the rest of the molecule.
10. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein R1 represents H or I.
11. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein R2 represents H.
12. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein R3 either represents:the wavy line represents the point of attachment to the rest of the molecule; or R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker is:where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule.
13. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein R3 represents -SELF IMMOLATIVE LINKER- PEPTIDE, where the self immolative linker is:where the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule.
14. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein when R3 represents -SELF IMMOLATIVE LINKER-PEPTIDE, the peptide is selected from:where the wavy line represents the point of attachment to the rest of the molecule.
15. The compound, or pharmaceutically acceptable salt or solvate thereof, according toClaim 14, wherein when R3 represents-SELF IMMOLATIVE LINKER-PEPTIDE, the peptide is:where the wavy line represents the point of attachment to the rest of the molecule.
16. The compound, or pharmaceutically acceptable salt or solvate thereof, according to any one of the preceding claims, wherein:R1 is I;R2is H;the wavy line represents the point of attachment to the rest of the molecule;where LINKER is n is 4;the wiggly line represents the point of attachment to the rest of the molecule;R3is -SELF IMMOLATIVE LINKER-PEPTIDE, where the self immolative linker iswhere the dotted line represents the point of attachment to the peptide and the wavy line represents the point of attachment to the rest of the molecule; and the peptidethe wavy line represents the point of attachment to the rest of the molecule.
17. A method for detection of cancer in vivo, the method comprising the following steps:(ai) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to any one of Clauses 1 to 16 to a subject; and(aii) detecting any chemiluminescence, wherein the presence of cancer in vivo is indicated by chemiluminescence.
18. A method of treating cancer, the method comprising the following steps:(bi) administering a compound of formula la or lb, or pharmaceutically acceptable salt or solvate thereof, according to any one of Clauses 1 to 16 to a subject; and(bii) subjecting the subject to X-ray irradiation.
19. The method according to Claim 18, wherein the compound of formula la or formula lb, or salt or solvate thereof, is a compound in which R4 is
Citation Information
Patent Citations
Chemiluminiscence substrate with high luminescence intensity, long wavelength and good stability and preparation method and application of chemiluminiscence substrate
CN110804009A
Organic compound, scintillator material and preparation method and application thereof
CN112174941A
Near-infrared chemiluminescent probes for in-VIVO imaging
WO2018216013A1
Ultrabright chemiluminescent probes for detection and imaging
WO2023018377A2
Cited By
Lysosome targeting probe as well as preparation method and application thereof
CN119823098A
